Document:

EX-10.18

 Exhibit 10.18 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 14-111 

15-0897 
 LICENSE AGREEMENT 

Between: THE UNIVERSITY OF BRITISH COLUMBIA 

and 
 GENOMEDX BIOSCIENCES INC. 

Table of Contents 
  

							
	Article	 	 	  	Page	 
			
	 1.0
	 	 DEFINITIONS
	  	 	2	 
	 2.0
	 	 PROPERTY RIGHTS IN & TO THE TECHNOLOGY
	  	 	7	 
	 3.0
	 	 GRANT OF LICENSE
	  	 	7	 
	 4.0
	 	 SUBLICENSING
	  	 	8	 
	 5.0
	 	 ROYALTIES
	  	 	8	 
	 6.0
	 	 ANNUAL LICENSE FEE
	  	 	10	 
	 7.0
	 	 PATENTS
	  	 	10	 
	 8.0
	 	 DISCLAIMER OF WARRANTY
	  	 	11	 
	 9.0
	 	 INDEMNITY & LIMITATION OF LIABILITY
	  	 	12	 
	 10.0
	 	 PUBLICATION & CONFIDENTIALITY
	  	 	13	 
	 11.0
	 	 PRODUCTION & MARKETING
	  	 	14	 
	 12.0
	 	 ACCOUNTING RECORDS & REPORTS
	  	 	14	 
	 13.0
	 	 INSURANCE
	  	 	15	 
	 14.0
	 	 ASSIGNMENT
	  	 	16	 
	 15.0
	 	 GOVERNING LAW
	  	 	16	 
	 16.0
	 	 NOTICES
	  	 	16	 
	 17.0
	 	 TERM
	  	 	17	 
	 18.0
	 	 TERMINATION OF AGREEMENT
	  	 	17	 
	 19.0
	 	 MISCELLANEOUS COVENANTS OF LICENSEE
	  	 	18	 
	 20.0
	 	 MANAGEMENT OF CONFLICTS OF INTEREST
	  	 	19	 
	 21.0
	 	 GENERAL
	  	 	20	 

 Schedules 
  

	 	“A”	 Description of “Technology” 

	 	“B”	 Payment Report 

	 	“C”	 UBC License Agreement Annual Report 

	 	“D”	 Address for Notices & Payment Instructions 

	 	“E”	 Patent Client and Billing Agreement 

	 	“F”	 List of Licensed Affiliated Companies 

	 	“G”	 Mandatory Sublicensing Provisions 

 UBC File:14-111 

LICENSE AGREEMENT 
 BETWEEN: 

THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at #103-6190
Agronomy Road, Vancouver, British-Columbia, V6T 1Z3 
 (“UBC”) 

AND: 
 GENOMEDX BIOSCIENCES INC., a
corporation incorporated under the Business Incorporation Act of British Columbia, with its offices at 1038 Homer St. Vancouver, BC, V6B 2W9 

(the “Licensee”) 
 WHEREAS: 

A. UBC has been engaged in Licensee sponsored research (UBC UILO CRA F11-044153) during the course of which it has invented and/or developed
certain technology relating to “Cancer Biomarkers and Classifiers and Uses Thereof’ (UBC UILO file 14-111), which research was undertaken by Peter Black (the “Investigator”) in the UBC Department of
Urologic Sciences; 
 B. The Licensee was granted an option to obtain a royalty bearing license to IP created under UBC CRA F11-044153, signed
October 1, 2011; 
 C. It is UBC’s objective to exploit its technology for the public benefit, and in a manner consistent with its Global
Access Principles, and status as a non-profit, tax exempt educational institution; and 
 C. The Licensee and UBC have agreed to enter into this license on the terms
and conditions set out in this Agreement. 
 THE PARTIES AGREE AS FOLLOWS: 
  

	1.0	 DEFINITIONS 

  

	1.1	 In this Agreement: 

  

	 	(a)	 “Affiliated Company” or “Affiliated Companies” means two or more corporations if the
relationship between them is one in which one of them is a subsidiary of the other, or both are subsidiaries of the same corporation, or 50% or more of the voting shares of each of them is owned or controlled by the same person, corporation or other
legal entity; 

  

	 	(b)	 “Agreement” means this license agreement; 

 

	 	(c)	 “Annual License Fee” is defined in Article 6.1; 

 

	 	(d)	 “Annual Report” means a report in the form referred to in Article 12; 

  
 Page 2 of 32 

 UBC File:14-111 
  

 

	 	(e)	 “Combination Product” means products commercialized by the Licensee that: 

 

	 	(i)	 include the Technology and/or any Improvements; 

 

	 	(ii)	 and one or more components, products or modules that have commercial utility and functionality separate from the
Technology and any Improvements, and when or if-such-components, products or modules are sold as stand-alone items, they would not infringe the Patents licensed under this Agreement (“Non-Covered Components”). 

 

	 	(f)	 “Confidential Information” means all information, regardless of its form, disclosed by one party to
the other and identified as “confidential” at the time of disclosure, except that “Confidential Information” does not include information: 

 

	 	(i)	 possessed by the recipient (the “Recipient”) before receipt from the disclosing party (the
“Discloser”), other than through prior disclosure by the Discloser, as evidenced by the Recipient’s business records; 

  

	 	(ii)	 published or available to the general public otherwise than through a breach of this Agreement; 

 

	 	(iii)	 obtained by the Recipient from a third party with a valid right to disclose it, provided that the third party is not
under a confidentiality obligation to the Discloser; or 

  

	 	(iv)	 independently developed by employees, agents or consultants of the Recipient who had no knowledge of or access to the
Discloser’s information as evidenced by the Recipient’s business records; 

 all information and documents
related to the Technology (including all derived analyses and conclusions), and the terms and conditions of this Agreement will be deemed Confidential Information of both parties. 

 

	 	(g)	 “Effective Termination Date” means the date on which this Agreement is terminated under Article 18;

  

	 	(h)	 “First Use of the Technology” means the earlier of either: 

 

	 	(i)	 the first use of the Technology or any Improvement, or 

 

	 	(ii)	 the first sale of a Product, 

in exchange for valuable consideration; 
  

	 	(i)	 “Improvements” means unencumbered improvements, variations, updates, modifications, and enhancements
made and/or acquired at any time after the Start Date by: 

  

	 	(i)	 the Investigator while employed at UBC, 

the Licensee , or 
  

	 	(ii)	 jointly, by the Investigator while employed at UBC, and the Licensee or any Sublicensees,

  
 Page 3 of 32 

 UBC File:14-111 
  

	 	 relating to the Technology which cannot be legally used or practiced without infringing the Patents licensed under this
Agreement; 

  

	 	(j)	 “Investigator” is defined in Recital “A”; 

 

	 	(k)	 “Multi-marker Product” is defined in Article 5.2; 

 

	 	(l)	 “Objectionable Material” is defined in Article 10.3; 

 

	 	(m)	 “Patents” means collectively the rights in and to any and all inventions which are disclosed in the
Canadian, U.S., and foreign patents and patent applications identified in Schedule “A” and all: 

  

	 	(i)	 counterparts, continuations, continuations-in-part, divisionals, continuing prosecution applications, and requests for
continued examinations, extensions, term restorations, renewals, reissues, re-examinations, or substitutions thereof; 

  

	 	(ii)	 corresponding international patent applications; 

 

	 	(iii)	 corresponding foreign patent applications, including supplementary protection certificates and other administrative
protections; and 

  

	 	(iv)	 international and foreign counterpart patents, 

resulting therefrom, all of which will be deemed added from time to time to Schedule “A”; 

 

	 	(n)	 “Payment Report” means a report in the form referred to in Article 12 setting out in detail how the
amount of Revenue and Sublicensing Revenue was determined; 

  

	 	(o)	 “Product(s)” means goods or services manufactured or provided in connection with the use of
all or some of the Technology and/or any Improvements, including Multi-marker Products; 

  

	 	(p)	 “Revenue” shall mean, subject to the adjustment set forth in Sections 5.3 and 5.4, the gross amount
of cash, cash equivalents, or in kind consideration of readily ascertainable value (for purposes of clarity, in kind consideration does not include any services received by Licensee or its Affiliated Companies from, or activities conducted by, a
third party pertaining to marketing, market development, promotions, advertising, training, education, outreach, clinical or validation studies, research, development and regulatory activities, unless those services were provided in lieu of payment
for Products or in lieu of royalties otherwise due from Sublicensees (in which case the fair market value of such services are to be included in Revenue or Sublicensing Revenue as the case may be)), received by Licensee, or its Affiliated Companies
for the transfer or provision of a Product to a third party (but not including Sublicensing Revenue), less documented: 

  

	 	(i)	 import, export, sales, excise or use taxes or duties, as well as freight, insurance and other shipping expenses, in
all such cases to the extent shown on the face of a Product invoice; 

  
 Page 4 of 32 

 UBC File:14-111 
  

 

	 	(ii)	 credits and refunds for defective or returned, rejected or recalled Products actually given; 

 

	 	(iii)	 regular trade, quantity, cash or other discounts, allowances, incentives, chargebacks, rebates and price reductions
actually given and reimbursement limitations actually imposed and incurred regarding a Product (in all such cases, whether-retroactively, contemporaneously or on a reasonably anticipated basis); and 

 

	 	(iv)	 actual allowances for bad debt or uncollectible amounts regarding sales of Products (provided that such allowances
have been formally designated as such in accordance with the Licensee’s internal accounting procedures consistently applied) to the extent included in amounts received by the Licensee. 

If not received in cash, other consideration received by the Licensee, or its Affiliated Companies to be used in calculating Revenue
shall be the fair market value of such other consideration. Revenue shall not include any amount for the sale or other transfer or provision of any Product to, by or between the Licensee and its Affiliated Companies unless the receiving party is the
end user of the Product, provided that any subsequent resale or re-transfer of such Product to an end user of the Product shall be included in Revenue. Revenue shall be determined from the books and records of Licensee and/or its Affiliated
Companies maintained in accordance with U.S. generally accepted accounting principles consistently applied. For the avoidance of doubt, any transfer or provision of Products at or below the manufacturing cost for use as samples, demonstration,
marketing or promotional purposes or research and development (including for clinical trials) shall not be deemed or give rise to Revenue. 
  

	 	(q)	 “Royalty Due Dates” means the last day of June and December of each year during the Term;

  

	 	(r)	 “Start Date” means 14 November, 2014; 

 

	 	(s)	 “Sublicensee” means any third party who has obtained directly or indirectly from or through the
Licensee any commercial rights to the Technology, any Improvements or Product, and shall include all sublicensees, that have entered into agreements with the Licensee for the use, development, evaluation,
co-development, partnered development, manufacture, distribution, marketing or sale of Products or granting rights to such third party in the Technology or any Improvements; 

 

	 	(t)	 “Sublicensing Revenue” means consideration directly or indirectly collected or received (including
without limitation royalties, initial, or periodic license fees, option payments, standstill payments, development or commercialization fees (subject to subsection (ii) below), milestone payments or any other payments unless excluded in this
definition) that Licensee receives or collects from a Sublicensee directly attributable to the grant of a sublicense to the Technology, any Improvements or Products, whether received in cash or other form, including amounts paid in excess of the
fair market value of any shares or other securities. For the avoidance of doubt: 

  
 Page 5 of 32 

 UBC File:14-111 
  

	 	(i)	 Sublicensing Revenue does not include 

 

	 	(A)	 the fair market value of payments or other consideration received for debt or equity; or 

 

	 	(B)	 reimbursement of costs or expenses actually incurred by Licensee. 

 

	 	(ii)	 Sublicensing Revenue will include all research or development fees received by the Licensee in connection with the
Technology, any Improvement, or any Products, in excess of the direct reimbursement for the actual costs of such research and development; 

  

	 	(iii)	 if a sublicense agreement to a Sublicensee includes either: 

 

	 	(A)	 a sublicense of one or more other biomarkers licensed to the Licensee under a royalty-bearing license with one or more
arm’s length third parties (other than from one of the Licensee’s own Sublicensees); and/or 

  

	 	(B)	 one or more biomarkers developed independently by the Licensee; 

and only to the extent such biomarker(s), whether licensed from a third party or developed independently by the Licensee, increase the
overall performance of a sublicensed Product, (a “Multi-marker Sublicense”), then the Sublicensing Revenue received by the Licensee under the Multi-Marker Sublicense shall be determined by multiplying the total Sublicensing Revenue
received under the Multi-marker Sublicense by the fraction A / (A + B), in which “A” is the number of biomarkers licensed to the Licensee under this Agreement, and “B” is the number of biomarkers licensed by the Licensee from one
or more arm’s length third parties (other than from one of its sublicensees) or those biomarkers developed independently by the Licensee (but only to the extent such biomarkers increase the overall performance of the Product), provided that the
fraction shall never be less than [***]. 
  

	 	(u)	 “Technology” means the Patents and all knowledge, know-how and/or technique or techniques invented,
developed and/or acquired, before the Start Date by the Investigator while employed at UBC or by the Licensee relating to, and including, the technology and materials described in Schedule “A”, as amended from time to time,
including, without limitation all related research, data, specifications, instructions, manuals, papers or other related materials of any nature at all, whether written or otherwise, and UBC’s Confidential Information; 

 

	 	(v)	 “Term” is defined in Article 17.1; and 

 

	 	(w)	 “Trade-marks” means any mark, trade-mark, service mark, logo, insignia, seal, design, symbol or
device used by UBC or Licensee in any manner at all. 

  

	 	(x)	 “Valid Claim” means (a) a claim of a pending application of the Patents or Licensee Patent(s)
which claim has been pending for [***] years or less, is being actively prosecuted in good faith and has not lapsed or gone abandoned; 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 6 of 32 

 UBC File:14-111 
  

	 	 (b) a claim of an issued or granted patent of the Patents or Licensee Patent(s)which claim has not expired, been
abandoned (including via admissions of invalidity and/or unenforceability), lapsed or been found to be invalid or unenforceable in a final decision of a court or other authority or agency of competent jurisdiction from which no appeal can be or is
taken; or (c) a supplementary protection certificate resulting from the expiry of an issued claim. 

  

	2.0	 PROPERTY RIGHTS IN & TO THE TECHNOLOGY 

2.1 UBC and the Licensee acknowledge and agree that the invention claimed in the [***] is jointly owned by UBC and the Licensee. 

2.2 Any Improvement made by UBC and the Licensee jointly in the course of practicing the Technology shall be jointly owned by UBC and the Licensee. 

2.3 On the last working day of December of each year during the Term, the Licensee will give notice to UBC of the details of all Improvements made by
the Licensee along with a summary report of activities conducted by the Licensee and any Sublicensees to practice and/or exploit the Technology during the previous year. 
  

	3.0	 GRANT OF LICENSE 

3.1 Subject to Article 3.3, UBC grants to the Licensee a worldwide, exclusive license to use and sublicense the Technology and any Improvements and to
manufacture, have made, distribute, sell, offer for sale, import, and export the Products on the terms and conditions set out in this Agreement. 

3.2 The license granted under this Agreement is granted only to the Licensee and any Affiliated Companies of the Licensee listed in Schedule
“F”, provided that: 
  

	 	(a)	 each Affiliated Company will perform the terms of this Agreement as if such Affiliated Company were a signatory to
this Agreement and each Affiliated Company agrees with UBC as primary obligor, to adopt as its own obligations every obligation of the Licensee contained or set forth in this Agreement; 

 

	 	(b)	 the Licensee unconditionally guarantees the performance of each Affiliated Company with the terms and conditions of
this Agreement; 

  

	 	(c)	 Affiliated Companies shall, at Licensee’s election, either by itself or through consolidated accounting with
Licensee, account for, and report, their sales of Product and receipts of Revenue on the same basis as if such sales or Revenues were the sales or Revenues of the Licensee, which shall then be included in the calculation of royalties due to UBC
under this Agreement; 

  

	 	(d)	 the obligations and liabilities of each Affiliated Company and the Licensee under this Agreement shall be joint and
several and UBC shall not be obliged to seek recourse against any Affiliate Company before enforcing its rights against the Licensee; and 

  

	 	(e)	 the Affiliated Companies shall not further sublicense the Technology or any Improvements or enter into sublicense
agreements with Sublicensees. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 7 of 32 

 UBC File:14-111 
  

The Licensee may amend Schedule “F” from time to time on written notice to UBC to include additional Affiliated Companies of the
Licensee. 
 3.3 The Licensee acknowledges and agrees that UBC may use the Technology and any Improvements without charge in any manner at all
for internal and non-commercial research, scholarly publication, educational and all other non-commercial uses. 
  

	4.0	 SUBLICENSING 

4.1 The Licensee may grant sublicenses of the Technology and/or any Improvements to Sublicensees without the prior written consent of UBC,
provided that each such sublicense agreement contain the mandatory sublicensing provisions set out in Schedule “G”. The Licensee will provide UBC with a signed copy of each sublicense agreement within 30 days of it being signed by
the Licensee and the Sublicensee provided that Licensee shall have the right to redact such sublicense agreement so long as the redacted copy is sufficient for UBC to verify Licensee’s compliance with this Section 4.1. 

4.2 Any sublicense agreement granted by the Licensee in full compliance with the requirements of this Agreement may be further sub-sublicensed without
the prior written consent of UBC, provided that such further sub-sublicense agreements also comply with the requirements of this Agreement, including without limitation the provisions of Article 4.1 applied mutatis mutandis to such
sub-sublicense agreement. 
  

	5.0	 ROYALTIES 

5.1 In consideration of the license granted under this Agreement, the Licensee will pay to UBC a royalty equal to [***]% of the Revenue. The
Licensee’s obligation to pay royalties on the Revenue shall commence on the date of the first sale of a Product by the Licensee and shall continue, on a Product-by-Product basis, until the expiration (or invalidation or unenforceability, as the
case may be) of the last Valid Claim within an issued Patent licensed under this Agreement covering the using or selling of such Product, after which time no royalties on the Revenue shall be due for the sale of such Product. 

5.2 In consideration of the license granted under this Agreement, the Licensee will pay to UBC a royalty equal to [***]% of the Sublicensing Revenue.

 5.3 If any product sold by the Licensee contains, in addition to one or more biomarkers licensed to the Licensee under this
Agreement, one or more royalty-bearing biomarkers licensed by the Licensee from one or more arm’s length third parties (other than from one of its Sublicensees) or those biomarkers were developed independently by the Licensee (and only to the
extent such biomarkers, whether licensed from a third party or developed independently by the Licensee, increase the overall performance of the Product) (a “Multi-marker Product”), then the Revenue attributable to the biomarker
licensed to the Licensee under this Agreement shall for the purposes of calculating the royalty payable in Article 5.1 be determined by multiplying the total Revenue received from the sale of the Multi-marker Product by the fraction A / (A + B), in
which “A” is the number of biomarkers licensed to the Licensee under this Agreement, and “B” is the number of biomarkers licensed by the Licensee from one or more arm’s length third parties (other than from one of its
sublicensees) or those biomarkers developed independently by the Licensee (but only to the extent such biomarkers increase the overall performance of the Product), provided that the fraction shall never be less than [***]. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 8 of 32 

 UBC File:14-111 
  

 

	 	(a)	 If any product sold by the Licensee in any country is in the form of a Combination Product, the Revenue attributable
to the license under this Agreement from the sale of such Combination Product shall be adjusted down by multiplying the actual total Revenue from such Combination Product in such country by the fraction A / (A + B) where A is the average invoice
price in such country of a Product containing the same amount of Product that is included in such Combination Product sold without the Non-Covered Components, when sold separately in such country, and B is the average invoice price of the Non-
Covered Component(s) containing the same amount of such Non-Covered Component that is included in such Combination Product in such country, when sold separately in such country. If, on a country-by-country basis, either the Product is not sold
without the Non-Covered Components and/or the Non- Covered Components are not sold separately, Revenue for the purpose of determining royalties of the Combination Product owed under this Agreement shall be reasonably determined in good faith based
on the relative values of the Non-Covered Components and the Product components. 

  

	 	(b)	 for the purposes of calculating the downward reduction, the fraction A / (A + B) shall never be less than [***].

 5.4 The royalty is due and payable within 30 days of each respective Royalty Due Date and is to be calculated with respect to the
Revenue and the Sublicensing Revenue in the six month period immediately before the applicable Royalty Due Date. For greater clarity it is confirmed that the [***]% royalty payable on Revenue under Article 5.1 will be calculated and payable by the
Licensee on both Revenue received by the Licensee, and on a “reach through” basis on all Revenue received by any Affiliated Companies, and the Licensee shall require all Affiliated Companies to completely and accurately report all such
Revenue, directly to UBC or through consolidated report by Licensee, at Licensee’s election. 
 5.5 All royalties paid by the Licensee to UBC
under this Agreement will be in U.S. dollars without any reduction or deduction of any nature or kind at all except as specifically set forth in this Agreement. If the Licensee receives any Revenue or Sublicensing Revenue in a currency other than US
dollars, the currency will be converted to the equivalent in US dollars on the date that any amount is payable to UBC, at the rate of exchange set by the Bank of Canada for buying Canadian dollars with such currency. The amount of US dollars
resulting from the conversion is to be included in Revenue or Sublicensing Revenue. 
 5.6 In addition to the above payments, the Licensee will pay to UBC milestone
payments of 
  

	 	(a)	 $[***] upon the first commercial sale (by the Licensee, any Affiliated Company or any Sublicensee) of the first
Product; 

  

	 	(b)	 $[***] once cumulative Revenue reaches $[***]; and 

 

	 	(c)	 $[***] once cumulative Revenue reaches $[***]. 

For clarity: a) each milestone payment referred to in this Article 5.7 will be payable once only, regardless of how many Products achieve such milestone
event; and b) for the purposes of calculating the $[***] and $[***] milestones, the cumulative Revenue from Multi- marker Products and Combination Products shall be subject the reductions set out in Articles 5.3 and 5.4. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 9 of 32 

 UBC File:14-111 
  

 

	6.0	 ANNUAL LICENSE FEE 

6.1 The Licensee will pay to UBC, in addition to all other amounts due under this Agreement, an annual license fee of $[***] (Canadian
funds) (the “Annual License Fee”). The Annual License Fee is payable, in advance, on or before January 1 of each year during the Term, starting on January 1, 2018 and will not be refunded to the Licensee (in whole or in
part) under any circumstances. 
  

	7.0	 PATENTS 

7.1 Subject to UBC’s approval, the Licensee will, after the execution of Schedule “E” by the appropriate parties, be
responsible for preparing, filing, prosecuting and maintaining the [***] jointly in UBC’s and the Licensee’s name and other patents claiming or covering the Technology or any Improvements in UBC’s name (the “Patent
Management”), and will ensure that the Patents broadly claim for UBC’s benefit all inventions disclosed by the Technology and any Improvements. The License will use its own patent counsel for the drafting and preparation of all
documents, filings, responses and correspondence, and UBC’s patent counsel (as identified in Schedule E) shall be the counsel of record with the patent agency and shall perform solely administrative functions such as calendaring, filing and the
like, as instructed by Licensee or its patent counsel in writing. The Licensee will provide to UBC all material information and documents received, prepared or filed in connection with the Patents. The Licensee agrees to use reasonable efforts to
include all reasonable comments and changes required by UBC as appropriate. 
 If the Licensee intends to abandon, allow to lapse, or not
continue the Patent Management of a Patent in any country, then the Licensee will not less than 60 days before any required action relating to such Patent notify UBC and UBC will then have the right, at its option, to assume the Patent Management of
such Patent, in which case such Patent will be excluded from the Patents licensed under this Agreement and Licensee will assign without further consideration its interest in such Patent (if jointly owned by the Licensee) to UBC. 

7.2 To assist the Licensee with the Patent Management, UBC will at the reasonable request of the Licensee, provide required information and will execute
and deliver documents and do such other reasonable acts as the Licensee may request. The Licensee will reimburse UBC for all reasonable costs incurred in complying with such requests. If there is any dispute between UBC and the Licensee relating to
any decision in connection with the Patents or the Patent Management then 
  

	 	(a)	 the Licensee will have the right to make the final decision to resolve such dispute on Patents that are jointly owned
by UBC and Licensee. 

  

	 	(b)	 UBC will have the right to make the final decision to resolve such dispute on Patents that are solely owned by UBC.

 7.3 Within 30 days of the date of any UBC invoice, the Licensee will reimburse UBC for [***] Patent expenses incurred by UBC both
before and after the Licensee has assumed the Patent Management. 
 7.4 The Licensee will not contest the validity or scope of any Patents licensed under this
Agreement. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 10 of 32 

 UBC File:14-111 
  

7.5 The Licensee will ensure proper patent marking for all uses of the Technology and any Improvements licensed under this Agreement and will clearly
mark the appropriate Patent numbers on any Products made using the Technology and any Improvements. 
  

	8.0	 DISCLAIMER OF WARRANTY 

8.1 UBC makes no representations, conditions or warranties, either express or implied, regarding the Technology or any Improvements or the Products.
Without limitation, UBC specifically disclaims any implied warranty, condition or representation that the Technology or any Improvements or the Products: 
  

	 	(a)	 correspond with a particular description; 

 

	 	(b)	 are of merchantable quality; 

 

	 	(c)	 are fit for a particular purpose; or 

 

	 	(d)	 are durable for a reasonable period of time. 

UBC is not liable for any loss, whether direct, consequential, incidental or special, which the Licensee or other third parties suffer arising from any
defect, error or fault of the Technology or any Improvements or Products, or their failure to perform, even if UBC is aware of the possibility of the defect, error, fault or failure. The Licensee acknowledges that it has been advised by UBC to
undertake its own due diligence regarding the Technology, any Improvements or Products. 
 8.2 Nothing in this Agreement: 

 

	 	(a)	 constitutes a warranty or representation by UBC as to title to the Technology or any Improvements or that anything
made, used, sold or otherwise disposed of under the license granted in this Agreement will not infringe the patents, copyrights, trade-marks, industrial designs or other intellectual property rights of any third parties, or any patents, copyrights,
trade-marks, industrial design or other intellectual property rights owned, in whole or in part, by UBC, or licensed by UBC to any third parties; 

  

	 	(b)	 constitutes an express or implied warranty or representation by UBC that the Licensee has, or will have the freedom to
operate or practice the Technology or any Improvements, or the freedom to make, have made, use, sell or otherwise dispose of Products; or 

  

	 	(c)	 imposes an obligation on UBC to bring, prosecute or defend actions or suits against third parties for infringement of
patents, copyrights, trade-marks, industrial designs or other intellectual property or contractual rights. 

 8.3 Notwithstanding
Article 8.2, if there is an alleged infringement of the Technology or any Improvements or any right with respect to the Technology or any Improvements, the Licensee may, on receiving the prior written consent of UBC, prosecute litigation designed to
enjoin infringers of the Technology or any Improvements. Provided that it has first granted its prior written consent, UBC agrees to reasonably co-operate to the extent of signing all necessary documents and to vest in the Licensee the right to
start the litigation, provided that all the direct and indirect costs and expenses of bringing and conducting the litigation or settlement are paid by the Licensee. All amounts recovered by the Licensee as the result of such litigation

  
 Page 11 of 32 

 UBC File:14-111 
  

will accrue to the benefit of the Licensee, provided that such amounts will be included in the Licensee’s Revenue and subject to payment of a
royalty to UBC in accordance with Article 5. 
 8.4 If any complaint alleging infringement of any patent or other proprietary rights is made against
the Licensee or a Sublicensee of the Licensee regarding the use of the Technology or any Improvements or the development, manufacture, use or sale of the Products, the following procedure will be adopted: 

 

	 	(a)	 the Licensee will promptly notify UBC on receipt of the complaint and will keep UBC fully informed of the actions and
positions taken by the complainant and taken or proposed to be taken by the Licensee on behalf of itself or a Sublicensee; 

  

	 	(b)	 except as provided in Article 8.4(d), all costs and expenses incurred by the Licensee or any Sublicensee of the
Licensee in investigating, resisting, litigating and settling the complaint, including the payment of any award of damages and/or costs to any third party, will be paid by the Licensee or any Sublicensee of the Licensee, as the case may be;

  

	 	(c)	 no decision or action concerning or governing any final disposition of the complaint will be taken without full
consultation with, and approval by, UBC; and 

  

	 	(d)	 UBC may elect to participate as a party in any litigation involving the complaint to the extent that the court may
permit, but any additional expenses generated by such participation will be paid by UBC (subject to the possibility of recovery of some or all of the additional expenses from the complainant), 

 

	9.0	 INDEMNITY & LIMITATION OF LIABILITY 

9.1 The Licensee indemnifies, holds harmless and defends UBC, its Board of Governors, officers, employees, faculty, students, invitees and agents against
any and all claims (including all associated legal fees and disbursements actually incurred) arising out of the exercise of any rights under this Agreement, including without limitation against any damages or losses, consequential or otherwise,
arising in any manner at all from or out of the use of the Technology or any Improvements or Products licensed under this Agreement by the Licensee or its Sublicensees or their customers or end-users. 

9.2 UBC’s total liability, whether under the express or implied terms of this Agreement, in tort (including negligence) or at common law, for any
loss or damage suffered by the Licensee, whether direct, indirect or special, or any other similar damage that may arise or does arise from any breaches of this Agreement by UBC, its Board of Governors, officers, employees, faculty, students or
agents, is limited to $10,000. 
 9.3 The parties acknowledges and agrees that neither party will be liable for consequential or incidental damages
arising from any breach or breaches of this Agreement, provided that the limitation set out in this Article 9.3: 
  

	 	(a)	 will not apply to limit the Licensee’s obligation to indemnify under Article 9.1; and 

 

	 	(b)	 will not apply to limit the Licensee’s liability to pay all financial obligations to UBC under this Agreement,
including without limitation royalties, milestone payments and the Annual License Fee or any other amounts due under this Agreement. 

  
 Page 12 of 32 

 UBC File:14-111 
  

9.4 Notwithstanding the termination or expiration of this Agreement, the rights and obligations in Article 9 will survive and continue to bind the
Licensee and its successors and permitted assigns. 
  

	10.0	 PUBLICATION & CONFIDENTIALITY 

10.1 Each party will keep and use the other party’s Confidential Information in confidence and will not, without the other party’s prior
written consent, disclose the other party’s Confidential Information to any person or entity, except to the party’s directors, officers, employees, faculty, students, actual and/or potential collaborators, investors and acquirers and
professional advisors who require the Confidential Information to assist such party in exercising its rights or performing its obligations under this Agreement or otherwise conducting its business. Each party will maintain an appropriate internal
program limiting the distribution of Confidential Information to only those officers, employees, actual and/or potential collaborators, investors, acquirers and professional advisors who require such Confidential Information in performing the
Licensee’s obligations under this Agreement and who have signed appropriate non-disclosure agreements. 
 10.2 Any party required by judicial or
administrative process to disclose the other party’s Confidential Information, will promptly notify the other party and allow it reasonable time to oppose the process before disclosing the Confidential Information. 

10.3 UBC is not restricted from presenting at symposia, national or regional professional meetings, or from publishing in journals or
other publications, accounts of its research relating to the Technology and any Improvements, provided that with respect to the Confidential Information only, the Licensee is provided with copies of the proposed disclosure at least 60 days before
the presentation or publication date and does not, within 30 days after delivery of the proposed disclosure, give notice to UBC indicating that it objects to the proposed disclosure. Any objection to a proposed disclosure will specify the portions
of the proposed disclosure considered objectionable (the “Objectionable Material”). On receiving notice from the Licensee that any proposed disclosure contains Objectionable Material, UBC and the Licensee agree to work together to
revise the proposed disclosure to remove or alter the Objectionable Material in a manner acceptable to both the Licensee and UBC, in which case the Licensee will withdraw its objection. UBC is not restricted from publishing or presenting the
proposed disclosure as long as the Objectionable Material has been removed. Any Objectionable Material will not be disclosed for 6 months from the date UBC delivered the proposed disclosure to the Licensee. After 6 months from the date UBC delivered
the proposed disclosure to the Licensee, UBC is free to present and/or publish the proposed disclosure whether or not it contains Objectionable Material. 

10.4 The Licensee requires of UBC, and to the extent permitted by law UBC agrees, that this Agreement, and each part of it, is confidential and will not
be disclosed to third parties, as the Licensee claims that the disclosure would or could reveal commercial, scientific or technical information and would significantly harm the Licensee’s competitive position and/or interfere with the
Licensee’s negotiations with prospective Sublicensees. Notwithstanding anything contained in Article 10, the Licensee acknowledges and agrees that UBC may identify the title of this Agreement, the parties to this Agreement and the names of the
inventors of the Technology and any Improvements, and that UBC may also disclose to the inventors the amount of all payments made to UBC by the Licensee under this Agreement, the manner or method by which such payments were calculated and all
Payment Reports delivered to UBC by the Licensee in connection with such payments. 

  
 Page 13 of 32 

 UBC File:14-111 
  

10.5 Notwithstanding the termination or expiration of this Agreement, the rights and obligations in Article 10 survive and continue to bind the parties,
their successors and permitted assigns. 
  

	11.0	 PRODUCTION & MARKETING 

11.1 Neither party will use the Trade-marks or make reference to the other party in any advertising or publicity, without the prior written consent of
the other party. Without limitation, the parties will not issue a press release regarding this Agreement or the Technology or any Improvements without first obtaining the other party’s written approval, except when the Licensee is required by
law or regulations (including rules and regulations of the Securities Exchange Commission) to disclose such information, in which event the Licensee will provide UBC with sufficient prior notice to permit UBC to bring an application or other
proceeding to contest the requirement. 
 11.2 The Licensee represents and warrants to UBC that it has the infrastructure, expertise and resources to: 

 

	 	(a)	 develop and commercialize the Technology and any Improvements; 

 

	 	(b)	 track and monitor on an ongoing basis performance under the terms of each sublicense entered into by the Licensee;

  

	 	(c)	 monitor patent infringement regarding any patent relating to the Technology and any Improvements licensed under this
Agreement; and 

  

	 	(d)	 handle the Technology and any Improvements with care and without danger to the Licensee, its employees, agents, or the
public. 

  

	12.0	 ACCOUNTING RECORDS & REPORTS 

12.1 The Licensee will maintain at its principal place of business, or another place as may be most convenient, separate accounts and records of all
Revenues, Sublicensees and Sublicensing Revenues, and all business done in connection with the Technology or any Improvements or Products. The accounts and records will be in sufficient detail to enable proper returns to be made under this Agreement
and the Licensee will cause its Affiliated Companies and Sublicensees to keep (and provide to the Licensee and UBC) similar accounts and records. 
 12.2 The Licensee
will complete and deliver to UBC: 
  

	 	(a)	 within 30 days of each and every Royalty Due Date, a completed Payment Report in the form attached as Schedule
“B”, (or an amended form as required by UBC from time to time) together with the royalty payable under this Agreement. A separate Payment Report will be prepared and delivered for each Sublicensee, including an accounting statement
setting out in detail how the amount of Sublicensing Revenue received from the Sublicensee was determined and identifying each Sublicensee and the location of the business of each Sublicensee. The first Payment Report will be submitted within 30
days of the first Royalty Due Date after the receipt of the first Revenue or Sublicensing Revenue, and thereafter a Payment Report will be delivered every 6 months regardless of whether any Revenue or Sublicensing Revenue was received in the
preceding period; and 

  
 Page 14 of 32 

 UBC File:14-111 
  

	 	(b)	 on or before June 1 of each year during the Term, starting on June 1 2016, the relevant sections of an
Annual Report in the form attached as Schedule “C” (or an amended form as required by UBC from time to time). 

12.3 The calculation of Revenue, Sublicensing Revenue and royalties will be carried out in accordance with US GAAP applied on a consistent basis.

 12.4 The Licensee will retain the accounts and records referred to in Article 12.1 for at least 6 years from when they were made and will permit
any duly authorized representative of UBC to inspect, at UBC’s expense and no more frequently than once per calendar year, the accounts and records during the Licensee’s normal business hours. The Licensee will provide to the
representative all reasonable evidence necessary to verify the accounts and records and will allow copies to be made of the accounts, records and agreements. If an inspection of the Licensee’s records by UBC shows an under-reporting or
underpayment by the Licensee of any amount to UBC, by more than [***]% or $[***] (whichever is higher) for any 12 month period, then the Licensee will reimburse UBC for the cost of the inspection as well as pay to UBC any amount found due (including
any interest) within 30 days of notice by UBC to the Licensee. 
 12.5 UBC will use reasonable efforts to ensure that all information provided to UBC
or its representatives under this Article 12 remains confidential and is treated as confidential by UBC. 
  

	13.0	 INSURANCE 

13.1 During the Term (and for a period which is the longer of either [***] years after the end of the Term, or [***] years after the last Product is
sold) the Licensee will procure and maintain insurance (including public liability and commercial general liability insurance), as would be acquired by a reasonable and prudent businessperson carrying on a similar line of business. 

13.2 Notwithstanding Article 13.1, one month before the earlier of the start of any clinical Product testing that will have an effect on,
or will influence, human health, diagnosis, or treatment (“Human Clinical Trials”) or the First Use of the Technology or any Improvement, the Licensee will give notice to UBC of the terms and amount of the product liability,
clinical trials, public liability, and commercial general liability insurance and such other types of insurance which it has placed. This insurance will: 
  

	 	(a)	 be placed with a reputable and financially secure insurance carrier; 

 

	 	(b)	 include UBC, its Board of Governors, faculty, officers, employees, students and agents as additional insureds with a
severability of interest and cross-liability clauses; 

  

	 	(c)	 provide coverage regarding all activities under this Agreement; 

 

	 	(d)	 provide that the policy cannot be cancelled or materially altered except on at least 30 days’ prior notice to
UBC. 

 13.3 The Licensee will provide to UBC certificates of insurance evidencing the coverage 7 days before the earlier of any
Human Clinical Trials or the First Use of the Technology. The Licensee will not: 
  

	 	(a)	 start any Human Clinical Trials, 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 15 of 32 

 UBC File:14-111 
  

	 	(b)	 allow the First Use of the Technology or any Improvement to occur; or 

 

	 	(c)	 sell any Product or allow any third party to use the Technology or any Improvement, 

at any time unless an insurance certificate is provided to UBC, and the insurance outlined in Article 13.2 is in effect. 

13.4 The Licensee will also require each Sublicensee to procure and maintain: 
  

	 	(a)	 public liability and commercial general liability insurance and such other types of insurance as would be acquired by
a reasonable and prudent businessperson carrying on a similar line of business; and 

  

	 	(b)	 in any event, one month before the earlier of any Human Clinical Trials or the First Use of the Technology or any
Improvement by the Sublicensee, product liability, clinical trials, public liability and commercial general liability insurance in reasonable amounts, with a reputable and financially secure insurance carrier. 

13.5 The Licensee will ensure that all Sublicensees’ policies of insurance include UBC, its Board of Governors, faculty, officers, employees,
students and agents as additional insureds. 
  

	14.0	 ASSIGNMENT 

14.1 Subject to Article 14.2, the Licensee will not assign, transfer or otherwise dispose of any or all of the rights granted to it under this Agreement
without the prior written consent of UBC, such consent not to be unreasonably withheld. 
 14.2 The Licensee may assign this Agreement as part of a
sale, transfer or merger of the Licensee’s entire business (or that part of Licensee’s business that exercises all rights granted under this Agreement. 

14.3 UBC will have the right to assign its rights, duties and obligations under this Agreement to a company of which it is the sole shareholder, or a
society which it has incorporated or which has purposes which are consistent with the objectives of UBC. If UBC makes such an assignment, the Licensee will release and discharge UBC from all obligations or covenants, provided that the company or
society, as the case may be, signs a written agreement which provides that the company or society assumes all obligations or covenants from UBC and that the Licensee retains all rights granted to the Licensee under this Agreement. 

 

	15.0	 GOVERNING LAW 

15.1 This Agreement is governed by, and will be construed in accordance with, the laws of British Columbia and the laws of Canada in force in that
province, without regard to its conflict of law rules. All parties agree that by executing this Agreement they have attorned to the jurisdiction of the Supreme Court of British Columbia. The parties agree that the British Columbia Supreme Court has
exclusive jurisdiction over this Agreement. 
  

	16.0	 NOTICES 

16.1 All reports and notices or other documents that a party is required or may want to deliver to any other party will be delivered: 

  
 Page 16 of 32 

 UBC File:14-111 
  

 

	 	(a)	 in writing; and 

  

	 	(b)	 either by personal delivery or by registered or certified mail at the address for the receiving party set out in
Article 16.2 or as varied by any notice. 

 Any notice personally delivered is deemed to have been received at the time of delivery.
Any notice mailed in accordance with this Article 16.1 is deemed to have been received at the end of the fifth day after it is posted. 
 16.2 The
address for delivery of notices and instructions for making payments to UBC are set out in the attached Schedule “D”. The address for delivery of notices to the Licensee is set out below: 

GenomeDx Biosciences 

1038 Homer St. 

Vancouver, BC V6B 2W9 
  

	 	Telephone:	 1.888.792.1601 

	 	Fax:	 1.855.324.2768 

  

	17.0	 TERM 

17.1 The term (the “Term”) of this Agreement starts on the Start Date and ends on the date on which all payment
obligations expire, upon which time the license to Licensee shall become fully-paid, royalty free, perpetual and irrevocable. 
  

	18.0	 TERMINATION OF AGREEMENT 

18.1 This Agreement automatically and immediately terminates without notice to the Licensee if any proceeding under the Bankruptcy and Insolvency Act of
Canada, or any other statute of similar purpose, is started by or against the Licensee and is not dismissed within 90 days. 
 18.2 UBC may, at its
option, terminate this Agreement by giving notice to the Licensee if one or more of the following occurs: 
  

	 	(a)	 the Licensee becomes insolvent, as evidenced for example (without limitation) by the appointment of a receiver or
receiver manager; 

  

	 	(b)	 any execution or other process of any court becomes enforceable against the Licensee, or if any similar process is
levied on the rights under this Agreement or on any money due to UBC and is not released or satisfied by the Licensee within 30 days from the process becoming enforceable or being levied; or 

 

	 	(c)	 any resolution is passed or order made or other steps taken for the winding up, liquidation or other termination of
the existence of the Licensee. 

  

	 	(d)	 if the Licensee breaches any of Articles 4.1, 11.1 or 13.1; 

 

	 	(e)	 if the Licensee, or any Affiliated Company is in breach of any other agreement between the Licensee or such Affiliated
Company and UBC and the breach has not been cured within the time provided for the curing of the breach under the terms of the other agreement. 

  
 Page 17 of 32 

 UBC File:14-111 
  

18.3 Other than as set out in Article 18.1, either party may terminate this Agreement for any breach which is not remedied after providing the following
notice to the party in breach: 
  

	 	(a)	 60 days’ notice in the case of any breach which can reasonably be remedied within 60 days of the delivery of such
notice; or 

  

	 	(b)	 if the breach cannot be remedied within 60 days and the breach is not remedied within such further period as may be
reasonably necessary, or within 90 days after receipt of notice, whichever is sooner. 

 18.4 If this Agreement is terminated under
Article 18.1, 18.2 or 18.3, the Licensee will make all outstanding royalty-payments to UBC under Articles 5 and 6, and UBC may proceed to enforce payment of all outstanding royalties or other monies owed to UBC and to exercise any or all of the
rights and remedies available under this Agreement or otherwise available by law or in equity, successively or concurrently, at the option of UBC. Within 5 days of the Effective Termination Date, the Licensee will deliver to UBC all Technology and
any Improvements in its possession or control and has no further right of any nature at all in the Technology or any Improvements. If the Licensee has not delivered up the Technology and any Improvements within 5 days from the Effective Termination
Date, UBC may immediately and without notice enter the Licensee’s premises and take possession of the Technology and any Improvements. The Licensee will pay all charges or expenses incurred by UBC in the enforcement of its rights or remedies
against the Licensee under this Article 18.4, including without limitation UBC’s legal fees and disbursements on an indemnity basis. 
 18.5 The
Licensee and all Sublicensees will cease to use the Technology or any Improvements in any manner at all or to manufacture or sell the Products within 5 days from the Effective Termination Date. The Licensee will then deliver to UBC an accounting
within 30 days from the Effective Termination Date. The accounting will specify, in or on such terms as UBC may in its sole discretion require, the inventory or stock of Products manufactured and remaining unsold on the Effective Termination Date.
UBC will instruct that the unsold Products be stored, destroyed or sold under its direction, provided this Agreement was terminated under Article 18.2 or 18.3. Without limitation, if this Agreement is terminated under Article 18.1, no Products will
be sold without the prior written consent of UBC. The Licensee will continue to make royalty payments to UBC in the same manner specified in Articles 5 and 6 on all Products that are sold in accordance with this Article 18.5, notwithstanding
anything contained in, or any exercise of rights by UBC, under Article-18.4. 
 18.6 Notwithstanding the termination or expiration of this Agreement,
Article 12 remains in full force and effect until 6 years after: 
  

	 	(a)	 all payments of royalty required to be made by the Licensee to UBC under this Agreement have been made by the Licensee
to UBC; and 

  

	 	(b)	 any other claim or claims of any nature or kind at all of UBC against the Licensee has been settled.

  

	19.0	 MISCELLANEOUS COVENANTS OF LICENSEE 

19.1 The Licensee represents and warrants to UBC that the Licensee is a corporation duly organized, existing and in good standing under the laws of
British Columbia and has the power, authority and capacity to enter into this Agreement and to carry out the transactions 

  
 Page 18 of 32 

 UBC File:14-111 
  

contemplated by this Agreement, all of which have been duly and validly authorized by all requisite corporate proceedings. 

19.2 The Licensee will comply with all laws, regulations and ordinances, whether Federal, State, Provincial, County, Municipal or otherwise, with
respect to the Technology and any Improvements and this Agreement. 
 19.3 The Licensee will pay all taxes and any related interest or penalty
designated in any manner at all and imposed as a result of the existence or operation of this Agreement, including without limitation tax which the Licensee is required to withhold or deduct from payments to UBC, but not any taxes based on
UBC’s income. he Licensee will provide to UBC evidence as may be required by Canadian authorities to establish that the tax has been paid. The royalties specified in this Agreement are exclusive of taxes. f UBC is required to collect a tax to
be paid by the Licensee or any of its Sublicensees, the Licensee will pay the tax to UBC on demand. 
 19.4 The obligation of the Licensee to make all
payments under this Agreement is absolute and unconditional and is not, except as expressly set out in this Agreement, affected by any circumstance, including without limitation any set-off, compensation, counterclaim, recoupment, defence or other
right which the Licensee may have against UBC, or anyone else for any reason at all. 
 19.5 The Licensee will pay interest on all undisputed amounts
due and owing to UBC under this Agreement but not paid by the Licensee on the due date, at the rate of [***]% per annum, calculated annually not in advance. The interest accrues on the balance of unpaid amounts from time to time outstanding, from
the date on which portions of the amounts become due and owing until payment in full. 
  

	20.0	 MANAGEMENT OF CONFLICTS OF INTEREST 

20.1 The Licensee acknowledges that it is aware of UBC’s Conflict of Interest Policy #97, Patent and Licensing Policy #88 and Research Policy #87
(www.universitycounsel.ubc.ca/policies/policies.html), and that UBC may amend these policies or introduce new policies from time to time 
  

	20.2	 Subject to Article 20.3 the Licensee and UBC agree, that: 

 

	 	(a)	 the facilities and research programs of the Licensee will be conducted independently of all UBC facilities, faculty,
students or staff, and in particular, independently of and from the Investigator and the laboratory facilities made available to the Investigator by reason of the Investigator’s employment at UBC; 

 

	 	(b)	 no students, post-doctoral fellows or other UBC staff will participate or be involved in the Licensee’s research,
projects or utilize its facilities; and 

  

	 	(c)	 any disclosures of inventions made by the Investigator to the Licensee will be immediately forwarded by the Licensee
to UBC. 

 20.3 The Licensee and UBC may, from time to time, enter into written agreements to permit activities which would
otherwise be prohibited by Article 20.2. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 19 of 32 

 UBC File:14-111 
  

21.0 GENERAL 
 21.1 Nothing contained in this Agreement
is to be deemed or construed to create between the parties a partnership or joint venture. No party has the authority to act on behalf of any other party, or to commit any other party in any manner at all or cause any other party’s name to be
used in any way not specifically authorized by this Agreement. 
 21.2 Subject to the limitations in this Agreement, this Agreement operates for the
benefit of and is binding on the parties and their respective successors and permitted assigns. 
 21.3 No condoning, excusing or overlooking by any
party of any default, breach or non-observance by any other party at any time or times regarding any terms of this Agreement operates as a waiver of that party’s rights under this Agreement. A waiver of
any term, or right under, this Agreement will be in writing signed by the party entitled to the benefit of that term or right, and is effective only to the extent set out in the written waiver. 

21.4 No exercise of a specific right or remedy by any party precludes it from or prejudices it in exercising another right or pursuing another remedy or
maintaining an action to which it may otherwise be entitled either at law or in equity. 
 21.5 All terms which require performance by the parties
after the expiry or termination of this Agreement, will remain in force despite this Agreement’s expiry or termination for any reason. 
 21.6
Part or all of any Article that is indefinite, invalid, illegal or otherwise voidable or unenforceable may be severed and the balance of this Agreement will continue in full force and effect. 

21.7 The Licensee acknowledges that the law firm of Richards Buell Sutton LLP has acted solely for UBC in connection with this Agreement and that all
other parties have been advised to seek independent legal advice. 
 21.8 This Agreement sets out the entire understanding between the parties and no
changes are binding unless signed in writing by the parties to this Agreement. 
 21.9 Time is of the essence of this Agreement. 

  
 Page 20 of 32 

 UBC File:14-111 

21.10 Unless the contrary intention appears, the singular includes the plural and vice versa and words importing a gender include other genders. 

SIGNED BY THE PARTIES AS AN AGREEMENT on the 4th            
day of February            , 2015 but effective as of the Start Date. 
 SIGNED FOR AND ON BEHALF
of 
 THE UNIVERSITY OF BRITISH COLUMBIA 
  

					
	 by its authorized signatories:
	  	 J.P. Heale, PhD, MBA

Interim Managing Director
 University-Industry Liaison Office
	  	

  

					
	 /s/ J. P. Heale
	 		 	
	  
 Authorized Signatory
	 		 	
	  
  

Authorized Signatory
	 		 	

 SIGNED FOR AND ON BEHALF of GENOMEDX 

BIOSCIENCES INC. 

					
	  
 by its authorized
signatories:
	 		 	
	  
 /s/ David Matthews
	 		 	
	  
 Authorized Signatory
	 		 	
			
	 David Matthews
	 		 	
			
	 Please print Name and Title of Signatory
	 		 	
			
	  
  

Authorized Signatory
	 		 	
			
	  
  

Please print Name and Title of Signatory
	 		 	

  
 Page 21 of 32 

 SCHEDULE “A” 

DESCRIPTION OF “TECHNOLOGY” 
  

							
	 [***]
	 	[***]	 	[***]	 	[***]
	
[***]
	 	[***]	 	[***]	 	[***]

  

	
	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
	Page 22 of 32

 SCHEDULE “B” 

Payment Report for the Period dd/mm/yy to dd/mm/yy 

Instructions for Completing this Report 
 Please fill out
each section in full, identifying in Royalty Summary Table the unit sales and geographical sales areas. If the license with UBC involves several product lines, please prepare a separate Summary Table for each product line. For Sublicensing Revenue
received from any Sublicensee, please prepare an additional report for each such Sublicensee. 
 PLEASE NOTE: An interest rate of [***]% per
annum, calculated annually not in advance will be assessed against all payments in arrears. 
  

											
	 Licensee
	 		 	Agreement #	 		 	UBC ID #	 	
	(or Sublicensee)	 	  
	 		 	  
	 		 	  

											
		
	UBC Technology	 	  

		
	Report Type (check one and complete as appropriate)	 	

											
		
	Single Product Line    ☐ Product Line Trade Name	 	  

											
		
	Multiple Products        ☐ Page        Of    
    Product Line Trade Name	 	  

											
		
	Sublicensee Report    ☐ Page        Of       	 	

   Payments this Quarter please complete separate tables for multiple product lines) Royalties on Product
Sales 
  

																							
	Country	  	Units
Sold	  	Unit Price
(domestic
currency)	  	Gross	  	Less
Allow-
ances*	  	Net	  	Royalty
Rate	  	Conversion
Rate (to
Canadian $)	  	Period Royalty
Amount (Canadian $)	 
	  	This yr	 	  	Last yr	 
	 Canada

US
 Europe

(specify countries)
  

Other
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	 	 	  	 	 	 
		  		  		  		  		  		  	Total Product Royalties	  	 	 	 	  	 	 	 

 Additional Payments (complete all that apply) 
  

															
	 Milestone Payment
	 	        	 		  	Amount  	  	 	  	 	  			
	 Annual License Fee
	 	 	 		  	Amount  	  	 	  	 	  			
		 		 		  		  	This Year	  	Last Year	  			
		 		 	 Total Payments for Period  
	  	 	  	 	  	 	    	 

 *Please indicate the reasons for returns or other allowances, if significant. Please note any unusual occurrences that
affected royalty amounts during the period. 
 Prepared by
                                         
                        Date
Dd/mm/yy                 Phone
                                         
                        
 I
                         (print name),
                             (title) hereby certify the foregoing information as true and correct.

  

	
	
               
                                         
                                         
                     

	Signature
                                         
                Date
Signed                        

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 23 of 32 

 UBC File:14-111 
  

SCHEDULE “C” 
 UBC License
Agreement Annual Report 
 The information to be completed below will constitute the annual report required under the UBC License Agreement. Any
information or documents provided by the Licensee in this report will not be interpreted as affecting the express rights and obligations of the Licensee contained in the License Agreement. This report is in addition to the Payment Report to
accompany each royalty payment. 
 Date of Report:
                                      Person Preparing This
Report:                                      

Name of Licensee:
                                 UBC File Number:    
                                 

Jurisdiction of Corporation:
                                         
                        Head Office
                                 

                            
                                         
                                        Address:
                                 

Contact Person for Company     
                                         
                                         
       
 Licensed Technology:
                                         
                                         
           
 Telephone Number:
                                        
     E-mail Address:
                                        

  

	1.	 Please provide a brief report on the status of development of the UBC Technology, progress on creating a commercial
Product or subsequent marketing of the Product as appropriate. 

  

	
	  
  

 

	2.	 Has the Licensee filed any patent applications for modifications or improvements relating to the original UBC
Technology? Please provide details, and attach copies of all relevant documents. 

  

	
	  
  

 

	3.	 Has the Licensee become aware of any potential 3rd party infringing on the UBC patents or related intellectual
property? If so please provide details and outline what the Licensee is doing about this. 

  

	
	  
  

 

	4.	 Has the Licensee met any milestone or performance objectives in the past year as set forth in the License Agreement?
Please outline the past year’s accomplishments 

  

	
	  
  

 

	5.	 Does the Licensee expect to meet any milestone or performance objective in the coming year as set forth in the License
Agreement? If so please provide details. 

  

	
	  
  

 

	6.	 Has the Licensee granted any sublicenses to 3rd parties? If so have copies of the sublicense agreement been provided
to the Technology Manager at UBC? If not, please enclose a copy of each proposed sublicense agreement. 

  

	
	  
  

 

	7.	 Has the Licensee made started any clinical trials or made any sales in the last 12 months? Yes
                         

No
                         

If so please submit a completed Royalty Payment Report. 

  
 Page 24 of 32 

 UBC File:14-111 
  

 

	 	a)	 Date of sales of Products utilizing the Technology; 

 

	 	b)	 Date of any clinical trials. 

 

	
	  
  

 

	8.	 Does your company have public liability insurance? If so, please attach a copy of the insurance policy naming UBC as
an insured as required by the License Agreement. 

  

	
	  
  

 

	9.	 Please provide the Licensee’s estimate or projection of gross sales revenue for products based on the UBC
Technology for the next 12 months by the Licensee and any sub-licensee. 

  

	
	  
  

 

	10.	 Is there any other information relating to this License that you think we should be aware of? Please summarize them
below or contact us directly. 

  

	
	  
  

Prepared by
                                         
    Date Dd/mm/yy      Phone
                                        
     
 I
                         (print name), of
                         (title) hereby certify the foregoing information as true and correct. 

 

	
	  

Signature
                                         
                                         
                                         
  Date Signed 
 Once completed, please submit this report to: 

Managing Director 

University — Industry Liaison Office 

#103 — 6190 Agronomy Road, 

Vancouver, BC 

V6T 1Z3 

  
 Page 25 of 32 

 SCHEDULE “D” 

ADDRESS FOR NOTICES & PAYMENT INSTRUCTIONS 
  

	1.	 The address for delivery of notices to UBC is: 

The Director 

University — Industry Liaison Office 

University of British Columbia 

#103 — 6190 Agronomy Road 

Vancouver, British Columbia 

V6T 1Z3 
 Telephone:
        (604) 822-8580 

Fax:                    (604)
822-8589 
  

	2.	 Payment of all amounts due to UBC under the terms of this license may be made as follows: 

 

	 	a)	 by cheque made payable to “The University of British Columbia” delivered to UBC at the above address; or

  

	 	b)	 by wire transfer in accordance with the instructions set out below: 

Note: Please ensure ALL of the information is provided for efficient receipt of wire payments: 

 

			
	    [***]
	  	 [***]

	 [***]
	  	
[***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]

 
 [***]

[***]
	  	 [***]

 
 [***]

[***]
  

	 	  	 [***]

 
 [***]

[***]

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 26 of 32 

 SCHEDULE “E” 

PATENT CLIENT AND BILLING AGREEMENT 
 BETWEEN:

 THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British
Columbia with offices at #103-6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3 (“UBC”) 
 AND: 

GENOMEDX BIOSCIENCES INC., a corporation incorporated under the Business Incorporation Act of British Columbia, with its
offices at 201-1595 W. 3rd Ave., Vancouver, BC, V6J 1J8 (“Licensee”) 
 AND: 

<->, a law firm with offices at <-> (the “Firm”) 

WHEREAS: 
 A. The Licensee and UBC have entered into a license
agreement under which UBC has licensed to the Licensee certain technology including the patents and patent applications listed in Appendix 1 (the “Patents”); 

B. UBC and the Licensee will use the Firm to prepare, file, prosecute and maintain the Patents; 

C. UBC will be the client of the Firm; and 
 D. UBC, the Licensee,
and the Firm have agreed to enter into this agreement to confirm the terms on which the Firm will be engaged to prepare, file, prosecute and maintain the Patents. 

THE PARTIES AGREE AS FOLLOWS: 
 1. While UBC is the client of
the Firm, UBC hereby authorizes the Firm to obtain and act in accordance with instructions directly from the Licensee (or its patent counsel) on all matters related to the preparation, filing, prosecution and maintenance of the Patents. The Firm
will copy UBC on all material documents and correspondence. 
 2. The Licensee is responsible for the payment of all fees, charges and disbursements
incurred by the Firm related to the preparation, filing, prosecution and maintenance of the Patents. The Firm will invoice the Licensee and will copy UBC on all such invoices. The Licensee will pay the Firm directly for all such fees, charges and
disbursements, and will copy UBC on each payment made. 
 3. Notices and copies of all documents and correspondence should be sent to the following:

  

							
		 	 To UBC:
	 	 Associate Director
	 	
		 		 	 University — Industry Liaison Office

		 		 	 The University of British Columbia

  
 Page 27 of 32 

							
		 		 	 #103 — 6190 Agronomy Road

		 		 	 Vancouver, British Columbia

		 		 	 V6T 1Z3
	 	
		 		 	 Telephone:
	 	 (604) 822-8580

		 		 	 Fax:
	 	 (604) 822-8589

				
		 	 To the Licensee:
	 	 <->
	 	
		 		 	 <->
	 	
		 		 	 Telephone:
	 	 <-> (

		 		 	 Fax:
	 	 <-> (

				
		 	 To the Firm:
	 	 <->
	 	
		 		 	 <->
	 	
		 		 	 Telephone:
	 	 <-> (

		 		 	 Fax:
	 	 <-> (

 SIGNED BY THE PARTIES AS AN AGREEMENT on the
                 day of
                                         
                           , 20     

 

					
			
	 THE UNIVERSITY OF BRITISH
	 	 )
	  	
	 COLUMBIA by its authorized signatory:
	 		  	
	     
	 		  	
		 	)	  	
	     
	 		  	
		 	)	  	
	     
	 		  	
	
                        
                                         
           
	 	)	  	
	     
	 		  	
	 Authorized Signatory
	 	)	  	
			
	 GENOMEDX BIOSCIENCES INC. by its
	 	)	  	
	 authorized signatory:
	 		  	
		 	)	  	
		 		  	
		 	)	  	
		 		  	
	
                        
                                         
           
	 	)	  	
			
	 Authorized Signatory
	 	)	  	
			
	 <            > by its authorized signatory:
	 	)	  	
	     
	 		  	
		 	)	  	
	     
	 		  	
		 	)	  	
		 		  	
	
                        
                                         
           
	 	)	  	
		 		  	

  
 Page 28 of 32 

					
	
                        
                                         
           
	 		  	
			
	 Authorized Signatory
	 	)	  	

  
  

Appendix “1” 
 List of Patents 

  
 Page 29 of 32 

 SCHEDULE “F” 

LIST OF LICENSED AFFILIATED COMPANIES 

  
 Page 30 of 32 

 SCHEDULE “G” 

MANDATORY SUBLICENSING PROVISIONS 
 The
Licensee (but not the Licensee’s Affiliated Companies) may grant sublicense agreements to Sublicensees without the prior written consent of UBC, provided that each such sublicense agreement (a “Sublicense Agreement”) meets the
requirements set out in the UBC - GenomeDx head license agreement (the “UBC License Agreement”) for sublicenses and the provisions of this Schedule “G”: 

 

	1.	 The Sublicensee shall acknowledge all ownership of the sublicensed Technology and any Improvements as set out in the
UBC License Agreement. 

  

	2.	 The Sublicensee shall acknowledge that UBC has the right to use the Technology and any Improvements without charge in
any manner at all for internal non-commercial research, scholarly publication, educational and other non-commercial uses, all in accordance with the terms of the UBC License Agreement. 

 

	3.	 Publication and Confidentiality: The Sublicensee shall comply with the publication and confidentiality obligations
with respect to UBC’s Confidential Information in accordance with Article 10 of the UBC License Agreement. 

  

	4.	 The Sublicensee shall agree not to use UBC’s name, trade-marks, service marks, logos, insignia, seal, or designs
without the prior written consent of UBC, except in a manner as permitted under Article 11.1 of the UBC License Agreement. 

  

	5.	 The Sublicensee shall procure and maintain insurance in full compliance with the terms of the UBC License Agreement
and will include UBC, its Board of Governors, faculty, officers, employees, students and agents as additional insured under the Sublicensee’s insurance. 

  

	6.	 The Sublicensee shall acknowledge and agree that UBC makes no representations, conditions or warranties, either
express or implied, regarding the Technology, Improvements or the Products. Without limitation, the Sublicensee shall acknowledge and agree that UBC specifically disclaims any implied warranty, condition or representation that the Technology,
Improvements or the Products: 

  

	 	(I)	 correspond with a particular description; 

 

	 	(ii)	 are of merchantable quality; 

 

	 	(iii)	 are fit for a particular purpose; or 

 

	 	(iv)	 are durable for a reasonable period of time. 

The Sublicensee shall acknowledge and agree that UBC is not liable for any loss, whether direct, consequential, incidental or special,
which the Sublicensee or other third parties suffer arising from any defect, error or fault of the Technology, Improvements or Products, or their failure to perform, even if UBC is aware of the possibility of the defect, error, fault or failure. The
Sublicensee shall acknowledge that it has been advised to undertake its own due diligence regarding the Technology, Improvements, and Products. 
  

	7.	 The Sublicensee shall acknowledge and agree that: 

 

	 	(a)	 UBC makes no warranty or representation as to title to the Technology or any Improvements or that anything made, used,
sold or otherwise disposed of under the Sublicense Agreement will not infringe the patents, copyrights, trade-marks, industrial designs or other intellectual property rights of any third parties, or any patents, copyrights, trade-marks, industrial
design or other intellectual property 

  
 Page 31 of 32 

	 	 
rights owned, in whole or in part, by UBC, or licensed by UBC to any third parties; 

  

	 	(b)	 UBC makes no express or implied warranty or representation that the Sublicensee has, or will have the freedom to
operate or practice the Technology or any Improvements, or the freedom to make, have made, use, sell or otherwise dispose of Products; or 

  

	 	(c)	 there is no obligation on UBC to bring, prosecute or defend actions or suits against third parties for infringement of
patents, copyrights, trade-marks, industrial designs or other intellectual property or contractual rights. 

  

	8.	 The Sublicensee shall indemnify, hold harmless and defend UBC and its Board of Governors, officers, employees,
faculty, students, invitees and agents against any and all claims (including all associated legal fees and disbursements actually incurred) arising out of the exercise by Sublicensee of any rights under the Sublicense Agreement, including without
limitation against any damages or losses, consequential or otherwise, arising in any manner at all from or out of the use of the Technology, Improvements or Products by the Sublicensee, or the Sublicensee’s Affiliated Companies,
sub-sublicensees or any of their respective customers or end-users. 

  

	9.	 The Sublicensee shall agree that UBC’s total liability, whether under the express or implied terms of the UBC
License Agreement or the Sublicense Agreement, in tort (including negligence) or at common law, for any loss or damage suffered by the Sublicensee, whether direct, indirect or special, or any other similar damage that may arise or does arise from
any breaches of the UBC License Agreement by UBC, its Board of Governors, officers, employees, faculty, students or agents, is limited to the amount of $[***] (Canadian funds). 

 

	10.	 The Sublicensee shall also acknowledge and agree that UBC will not be liable for consequential or incidental damages
arising from any breach or breaches of the UBC License Agreement or the Sublicense Agreement. 

  

	11.	 The Sublicensee shall acknowledge that in consideration of the grant of the Sublicense Agreement and the grant
thereunder of a sublicense to UBC’s interest in the Technology and Improvements, UBC shall, as a third party beneficiary, be entitled to enforce against the Sublicensee at UBC’s discretion, and for UBC’s benefit, those provisions
contained in the Sublicense Agreement for UBC’s benefit. 

 [***]=CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

  
 Page 32 of 32EX-10.19

 Exhibit 10.19 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 Confidential 

Execution Copy 

SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (this “Agreement”), dated as of June 7, 2019 (the “Effective
Date”), is made by and between Affymetrix, Inc., a Delaware corporation that is part of Thermo Fisher Scientific Inc., having its principal office at 3450 Central Expressway, Santa Clara, California 95051 (“Affymetrix”),
and Decipher Biosciences, Inc., a Delaware corporation with offices at 10355 Science Center Drive, Suite 240, San Diego, CA 92121 (referred to generally as “Partner,” and also as “Buyer” in Schedule B).
Affymetrix and Partner are each referred to individually as a “Party,” and together as the “Parties.” 

WHEREAS, Affymetrix, Inc. and GenomeDx Biosciences Inc. entered into that certain Powered by Affymetrix Agreement dated as of
March 6, 2014, which was amended on March 5, 2017 (the “2014 Agreement”); 
 WHEREAS, Affymetrix
was acquired by Thermo Fisher Scientific Inc. on March 31, 2016; 
 WHEREAS, GenomeDx Biosciences Inc. changed its name
to GenomeDx Inc. in connection with its re-domicile from British Columbia to Delaware in July 2018, and then changed its name to Decipher Biosciences, Inc. in January 2019; and 

WHEREAS, the Parties wish to terminate the 2014 Agreement and enter into this new Agreement as of the Effective Date. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE I 

DEFINITIONS 

Section 1.01 Definitions. 

As used throughout this Agreement, each of the following terms shall have the respective meaning set forth below: 

“Affiliate” of a Party means any entity that directly or indirectly controls, is controlled by or is under
common control with such Party. “Control” (and, with correlative meanings, the terms “controlled by” and “under common control with”) means, in the case of a corporation, the ownership of
more than fifty percent (50%) of the outstanding voting securities thereof or, in the case of any other type of entity, an interest that results in the ability to direct or cause the direction of the management and policies of such entity or the
power to appoint more than fifty percent (50%) of the members of the governing body of the entity, or if not meeting the preceding requirement, any company owned or controlled by or owning or controlling a Party at the maximum control or ownership
right permitted in the country where such Party exists. 
 “Affymetrix Intellectual Property Rights” means
all Intellectual Property Rights owned or controlled as of the Effective Date or thereafter during the Term by Affymetrix (exclusive of Affiliates) 

 
that would be infringed, absent a license, by the manufacture, import, use, sale or offer for sale of Diagnostic Products or Diagnostic Services in the Territory. 

“Affymetrix Products” means Arrays, reagents, and any other products sold to Partner by Affymetrix pursuant
to this Agreement. 
 “Array” means the [***], supplied to Partner by Affymetrix, and any future version of
such product. 
 “Blanket PO” has the meaning set forth in Section 3.01. 

“Cap” has the meaning set forth in Section 5.04. 

“Change of Control” of a Party shall mean if: (i) any third party acquires directly or indirectly the
beneficial ownership of any voting security of such Party, or if the percentage ownership of such person or entity in the voting securities of such Party is increased through stock redemption, cancellation or other recapitalization, and immediately
after such acquisition or increase such third party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting power of all of the then- outstanding voting securities of such
Party, except in connection with any change in domicile or in an equity financing transaction; (ii) a merger, consolidation, recapitalization, or reorganization of such Party is consummated, other than any such transaction which would result in
stockholders or equity holders of such Party or an Affiliate of such Party immediately prior to such transaction owning at least fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity) immediately following
such transaction; or (iii) an agreement for the sale or disposition by such Party of all or a substantial portion of such Party’s assets, other than to an Affiliate. 

“Confidential Information” has the meaning set forth in Section 5.01. 

“Diagnostic Product” means a product that is: (a) developed by Partner using the Affymetrix Products or
into which a Affymetrix Product is incorporated, and (b) marketed and sold solely under a Partner-branded label, with such product to be: (i) used for the testing of human patients and approved for use and distribution by the relevant
Regulatory Authorities, if applicable; and (ii) used and distributed in accordance with all laws and regulations of the jurisdictions in which it is being used and distributed. 

“Diagnostic Service” means, pursuant to approval by the FDA, CLIA or other relevant Regulatory Authorities
(as defined in Schedule C) for the jurisdictions in which the Diagnostic Product is being used if applicable and/or required, marketed or placed into commercial distribution, and in accordance with all laws and regulations governing such
service: (i) receiving a biological sample directly from a caregiver; (ii) applying the sample to the Diagnostic Product; reading and analyzing the experimental results; and (iv) providing, if deemed appropriate by the laboratory
performing the test, the diagnostic results directly back to the same caregiver for use in the Field. 
 “Disclosing
Party” has the meaning set forth in Section 5.01. 
 “Field” as of the Effective Date, means
the screening, detection and prognosis of cancer. 
 “Intellectual Property Rights” means legally
enforceable rights in intangible property in the form of patents, pending patent applications, trademarks, copyrights, trade secrets, know how, mask works, and 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 2 

 
other proprietary information including without limitation, specifications, data, technical, commercial, financial, regulatory and other confidential information, or any other form of
intellectual property as protected by law. 
 “Instrument” means either (i) the [***], or (ii) [***],
which is FDA-cleared, CE-IVD marked and regulatory cleared in multiple countries. 

“Payment Plan” has the meaning set forth in Section 5.11. 

“Probe” means a single species of oligonucleotide designed to be affixed to one or more arrays to detect one
or more analytes or the description or disclosure of such an oligonucleotide. 
 “Receiving Party” has the
meaning set forth in Section 5.01. 
 “Release Order” has the meaning set forth in Section 3.01.

 “Term” has the meaning set forth in Section 5.03. 

“Territory” means worldwide. 

[***] 

Other capitalized terms have the meaning set forth in the body of this Agreement. 

ARTICLE II 
 DIAGNOSTIC PRODUCTS
AND SERVICES 
 Section 2.01 Diagnostic Rights. 

Affymetrix hereby grants Partner a non-exclusive,
non-sublicensable, non-transferable license, subject to the exclusions set forth below, in the Territory to the Affymetrix Intellectual Property Rights to:
(i) make, have made, use, market, sell, offer for sale, import and distribute (including via multiple levels of distributors) Diagnostic Products for use in the Field; and (ii) provide Diagnostic Service(s) in the Field (but excluding any
right to make or have made Arrays. Notwithstanding the foregoing, this Agreement does not convey to Partner any right to (i) make or have made any Affymetrix Product or any component thereof, or (ii) sell Affymetrix Products on a
stand-alone basis, as a component of or bundled with any products or services except as part of Diagnostic Products and Diagnostic Services. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 3 

 Section 2.02 Licenses of Third Party Intellectual
Property Rights, Content or Applications. 
 Partner will be solely and exclusively responsible for securing all licenses
necessary to utilize any third party Intellectual Property Rights, or applications for use in connection with the Diagnostic Products and Diagnostic Services, and Partner will be solely and exclusively responsible for assuming all financial
obligations associated with such licenses entered into by Partner, including payment of any upfront fees, milestone payments, and/or royalties; and Partner will be responsible for granting licenses to third parties that may be required to enable
such third parties to use Partner’s Intellectual Property Rights, or applications in connection with the Diagnostic Products and Diagnostic Services. 

Section 2.03 Partner Intellectual Property Rights. 

All Intellectual Property Rights of Partner existing at the time of the Effective Date and coming into existence thereafter
shall remain the property of Partner and this Agreement does not effectuate any transfer of such Intellectual Property Rights to Affymetrix nor shall Affymetrix claim any right or title to such Intellectual Property Rights as a result of this
Agreement. 
 Section 2.04 Support for Partner. 

Affymetrix covenants to Partner that Affymetrix will support, and make available for use and sale, both Arrays and the
Instruments used in connection with such Arrays in a manner consistent with the level of support provided to Affymetrix’s diagnostic instrument partners generally and on Affymetrix’ customary terms and conditions, for the Tenn.
Notwithstanding anything to the contrary, and for the purpose of clarification, the Parties acknowledge and agree that no right to resell, transfer or distribute any Instrument is granted under this Agreement. 

Section 2.05 Shipment of Arrays to [***]. 

Pursuant to Section 12 of the Affymetrix Terms and Conditions of Sale attached as Schedule B, Affymetrix agrees to
allow Partner to ship Arrays to [***]. Affymetrix hereby authorizes [***] to use Partner’s Diagnostic Products incorporating the Decipher Arrays solely for the purpose of [***]. [***] 

If Affymetrix discovers that [***] is using an Array for any other purpose, Affymetrix will notify the Partner and the Partner
will have [***] days from such notice to remedy the situation or the Partner’s right to ship Arrays to [***] may be revoked by Affymetrix. 

Partner represents and warrants that: [***]. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 4 

 For purposes of clarification, Partner [***] is the purchaser of all Arrays
supplied under this Agreement. Partner acknowledges that, as the purchaser, it must manage any warranty claims related to an Array that Partner has shipped to [***]. 

ARTICLE III 
 AFFYMETRIX PRODUCT
SUPPLY 
 Section 3.01 Product Orders. 

Partner shall place a Blanket Purchase Order (“Blanket PO”) for the balance of calendar year 2019 within ten
(10) days of the Effective Date. 
 Partner shall place a Blanket PO for calendar year 2020 by [***], and for
subsequent calendar years during the Term by [***] of the previous calendar year. 
 Each Blanket PO shall contain the
following information: (a) minimum annual quantity of Arrays and reagents in accordance with Schedule A, (b) forecasted quantities per month, and (c) a schedule of forecasted shipment release dates. Notwithstanding the
foregoing, the Blanket PO for the balance of calendar year 2019 shall be for a minimum of [***] Arrays, and the first scheduled shipment date cannot be less than [***] days from the date of the Blanket PO. 

Partner shall place release orders under each Blanket PO in accordance with the forecasted monthly quantities and scheduled
shipment dates set forth in each Blanket PO for Affymetrix Products such that all Arrays and reagents are delivered within the calendar year for that Blanket PO (each, a “Release Order”). Each Release Order shall be sent by written
or electronic purchase order to Affymetrix. Affymetrix shall be obligated to accept and fill all Release Orders for Affymetrix Products to the extent that they are in accordance with the Blanket PO, as defined above. Affymetrix will use commercially
reasonable efforts to fulfill any additional purchase orders that exceed the Blanket PO, or inform Partner of any anticipated delays, in a timely manner. Partner may purchase any Array under this Agreement for any Affiliate or diagnostic laboratory
performing the Diagnostic Services on behalf of Partner. 
 Section 3.02 Supply of Arrays. 

Affymetrix will manufacture the Arrays in a facility that adheres to Quality Management System Requirements (ISO 13485:2003)
under current Good Manufacturing Practices (cGMP), 21 C.F.R. Sec. 820. 
 Section 3.03
[Intentionally omitted]. 
 Section 3.04 Terms and Conditions of Sale. 

The Terms and Conditions of Sale for the supply of Affymetrix Products hereunder are attached hereto as Schedule B.
Notwithstanding anything to the contrary in Schedule B: (a) Partner will pre-pay for the Affymetrix Products ordered under this Agreement until Partner has paid all amounts due under the Payment
Plan attached as Schedule F, after which time Partner will pay for Affymetrix Products 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 5 

 
within [***] days of the date of the invoice, and (b) Affymetrix Products will be shipped [***]. 

Section 3.05 Force Majeure. 

In the event that either Party is prevented from performing any of its obligations under this Agreement (except for
Partner’s payment obligations) due to any cause beyond the reasonable control of such Party, and such Party shall have used all reasonable efforts to avoid, or mitigate the effects, of such occurrence, such Party shall promptly provide written
notice to the other Party describing such circumstances, and thereupon the affected Party’s performance shall be excused and the time for performance shall be extended for the period of delay or inability to perform due to such occurrence. 

Section 3.06 Product Discontinuation. 

In the event that Affymetrix decides to discontinue the manufacture of either Instrument, Affymetrix will provide Partner at
least [***] written notice of its intent to discontinue the sale of such Instrument, and Affymetrix will continue to offer service and support for such Instrument for [***] after the date of discontinuation. 

ARTICLE IV 
 PURCHASE COMMITMENTS;
PAYMENT 
 Section 4.01 Product Purchase and Supply Commitments. 

Partner will purchase Arrays and other Affymetrix Products for use in the Field at the pricing as set forth on Schedule
A. 
 As stated in Section 3.01, Partner will place Release Orders under each Blanket PO such that all Arrays are
delivered within the calendar year for that Blanket PO. If Partner fails to purchase the total quantity of Arrays set forth in any Blanket PO within that calendar year, Affymetrix will invoice Partner for the difference between the actual price paid
and the total price that would have been paid had Partner purchased the total quantity of Arrays set forth in the Blanket PO. 

Section 4.02 Price Adjustment for Affymetrix Products. 

Affymetrix will provide Partner with [***] days’ written notice of any price adjustments made in accordance with Schedule
A. 
 Section 4.03 Regulatory Issues. 

Partner and Affymetrix hereby agree to comply with their respective obligations under the Regulatory Terms and Conditions
attached hereto as Schedule C. 
 Section 4.04 Taxes. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 6 

 Any tax that is owed by Affymetrix or its Affiliates by reason of the
execution or the performance of this Agreement and that is required to be paid or withheld by Partner under US law, including income taxes (other than Affymetrix’ income taxes), stamp taxes, registration taxes or fees, turnover taxes, or
withholding taxes, shall be withheld from any payments due to Affymetrix pursuant to this Agreement and paid when due by Partner or its Affiliates on behalf of Affymetrix or its Affiliates to the appropriate governmental authority. Payments made by
Partner to Affymetrix for Affymetrix Products pursuant to this Agreement shall be reduced by the amount of tax paid by Partner on behalf of Affymetrix or its Affiliates, and Partner or its Affiliate shall furnish Affymetrix or its Affiliates with
proof of payment of such tax, together with official or other appropriate evidence issued by the appropriate governmental authority, sufficient to enable Affymetrix or its Affiliates to support a claim in respect of any sum so withheld. Any such tax
required to be paid or withheld shall be an expense of and borne by Affymetrix or its Affiliates. 
 ARTICLE V 

MISCELLANEOUS 

Section 5.01 Confidential Information. 

Neither Party shall disclose to any third party any Confidential Information of the other, nor use the Confidential Information
of the other, for any purpose other than exercising its rights or carrying out its obligations under this Agreement. Each Party shall ensure that its and its Affiliates’ employees, officers, representatives and agents do not disclose to third
parties any Confidential Information of the other, and do not use the Confidential Information of the other for any purpose other than exercising its rights or carrying out its obligations under this Agreement. Upon the termination of this
Agreement, each Party shall return to the other or destroy all Confidential Information in its possession except such Confidential Information stored on such Party’s electronic backup system; provided that each Party may retain one copy for
archival purposes only. Each party hereto may disclose Confidential Information of the other Party to the extent such disclosure is (i) necessary for complying with applicable governmental laws or regulations of governmental or other agencies
(including, but not limited to, the United States Food and Drug Administration, the United States Securities and Exchange Commission or the National Association of Securities Dealers); (ii) necessary for complying with a court order;
(iii) otherwise required to be submitted to tax or other governmental authorities; or (iv) to existing or potential acquirers or merger candidates; sub-licensees or collaborators; auditors;
attorneys; investment bankers; existing or potential investors, venture capital firms or other financial institutions or investors for purposes of obtaining financing; or Affiliates, each of whom prior to disclosure must be bound by obligations of
confidentiality and non-use at least equivalent in scope to those set forth in this Agreement; provided that, in the case of (i)-(iii) above, if a Party is required to make any such disclosure, it will give
reasonable advance notice to the other Party of such disclosure and will use its commercially reasonable efforts to secure confidential treatment of such information in consultation with the other Party prior to disclosure (whether through
protective orders or otherwise) and will in any event disclose only the minimum necessary to comply with such requirements. 

“Confidential Information” means all proprietary and confidential information and materials of a Party that
is disclosed or made available by observation or analysis by or on behalf of such Party (the “Disclosing Party”) to the other Party (the “Receiving Party”), and which the Disclosing Party either: (i) marks as
confidential or proprietary at the time of disclosure; or (ii) in the case of verbal disclosures, identifies as confidential or proprietary at the time of disclosure and confirms the same in writing within thirty (30) calendar days of
disclosure; provided, however, that a failure to so mark or identify shall not affect in any manner the confidential nature or status of information disclosed by Discloser or Recipient’s obligations to keep such Confidential Information
secret and confidential as provided hereunder. 

  
 7 

 Confidential Information includes, but is not limited to: business, financial and technical
information, the terms of this Agreement, designs, formulations, methods, techniques, methodology, equipment, data, reports, laboratory notebooks, know-how, sources of supply, Partner and supplier lists,
patent strategy and business plans, information concerning products in development; provided that “Confidential Information” shall not include information which: (i) was known to the Receiving Party at the time it was disclosed
free of any obligation of non-disclosure, as evidenced by written records existing at the time of disclosure; (ii) is, at the time of disclosure, or later becomes publicly known under circumstances
involving no breach of this Agreement or the breach of any other agreement; (iii) lawfully and in good faith becomes available from a third party who has the right to disclose it; or (iv) was independently created by personnel of the
Receiving Party without any reference to the Disclosing Party’s Confidential Information, as evidenced by written records. The disclosure of Confidential Information hereunder shall not result in any right or license to the Receiving Party for
use or exploitation of such information. Each Receiving Party’s obligations with respect to the Confidential Information of the Disclosing Party, including Confidential Information shared under the 2014 Agreement, shall survive for [***]
following the termination or expiration of this Agreement. 
 Section 5.02 Use of Name; Public
Statements. 
 Except as set forth in this Agreement, neither Party shall use Confidential Information of the other Party
in any publication, press release, promotional material or other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by the foregoing shall not prohibit either Party from making any
disclosure identifying the other Party that is required by applicable law. Each Party shall have the right to issue press releases and to make other public disclosures, presentations or publications with respect to this Agreement (pursuant to
filings with the Securities and Exchange Commission or otherwise); provided, however, that no such press release or other public disclosure, presentation or publication shall disclose any Confidential Information of the other Party without the prior
written consent of such other Party. The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of the initial press release regarding this Agreement, if any, and any subsequent press releases or
other disclosures prior to the issuance thereof, provided that a Party may not unreasonably withhold consent to such releases or disclosures, and that either Party may issue such press releases or make such disclosures as it determines, based on
advice of counsel, are reasonably necessary to comply with applicable laws or for appropriate market disclosure. In addition, following the initial press releases announcing this Agreement, either Party shall be free to disclose, without the other
Party’s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance herewith. 

Section 5.03 Term and Termination. 

Term. Unless earlier terminated in accordance with this Section 5.03, this Agreement shall remain in effect until
December 31, 2023 (the “Initial Term”). Thereafter, this Agreement will renew for an additional four calendar years (“Renewal Term”), unless one Party gives the other Party written notice of its intent not to
renew at least six months prior to the expiration of the Initial Term. The Initial Term combined with the Renewal Term, if any, is referred to as the “Term.” 

Material Breach. In the event of a material breach by either Party of the terms of this Agreement, the other Party will
have the right to send written notice to the allegedly breaching Party identifying such breach. If a Party receives notice of material breach and such breaching Party fails to cure such breach within forty-five (45) days after giving such
breaching Party written notice by express or 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 8 

 
registered mail (or within ten (10) days’ notice in the event such breach is solely based upon the breaching Party’s failure to pay any amounts due hereunder), return receipt
requested, the non-breaching Party may terminate this Agreement by delivering written notice of termination to the breaching Party. Such forty-five (45) day or ten (10) day period shall be tolled during the pendency of any legal action in
which a Patty is disputing the existence of a material breach. 
 Failure to Supply. Partner may terminate this
Agreement immediately upon ninety (90) days prior written notice to Affymetrix in the event Affymetrix fails to deliver to Partner at least [***] of the quantity of Affymetrix Products ordered as part of the Blanket PO for [***] consecutive
quarters. 
 Government Action. Either Party may terminate this Agreement immediately upon written notice to the
other Party if Affymetrix has received written communication from any governmental authority or court stipulating the cessation of the production or sale of the Arrays. Partner may terminate this Agreement immediately upon written notice to
Affymetrix if it decides, or is required by any governmental authority, to cease all commercialization of Diagnostic Products and Diagnostic Services. For purposes of this Section, Partner may terminate this Agreement upon ninety
(90) days’ written notice to Affymetrix if Partner decides to cease or suspend commercialization of Diagnostic Products or Diagnostic Services as a result of a material reduction in Medicare, Medicaid or other applicable third party payor
reimbursement rates. 
 Termination by Partner. Partner may terminate this Agreement upon ninety (90) days prior
written notice to Affymetrix for any reason. 
 Survival of Obligations upon Expiration or Termination. Upon the
expiration of this Agreement, or termination of this Agreement upon any of the grounds set forth above in the sub-sections entitled Material Breach, Failure to Supply, Government Action and Termination By
Partner, all rights and obligations of the Parties shall cease to have effect immediately provided that the following sections of this Agreement shall survive: Sections 3.04, 4.01 and 4.04, Article 5 (Miscellaneous), Article 1 Definitions, and such
other provisions of this Agreement to the extent necessary to give meaning to the abovementioned provisions. Termination or expiration of this Agreement shall not affect any rights or liabilities of either Party which may have accrued up to the date
of such termination or expiration. Upon termination of this Agreement, Partner agrees to purchase all inventory on-hand (built per a PO from Partner and no greater than the amount in such PO) associated with
the supply of the Affymetrix Products pursuant to this Agreement at the time of the notification. 

Section 5.04 Indemnity. 

Affymetrix shall indemnify and hold harmless Partner, its Affiliates and its and their officers, directors, employees, agents
and representatives against any third party suit or proceeding brought against Partner or its Affiliates and its and their officers, directors, employees, agents and representatives to the extent based on (i) a claim that Affymetrix Product
directly infringes a valid and enforceable patent, copyright or trade secret right that exists as of the Effective Date in the United States, or (ii) Affymetrix’s breach of its obligations or warranties under this Agreement, and Affymetrix
shall pay damages and costs finally awarded against Partner resulting therefrom and reasonable costs of investigation or settlement and legal fees and accounting expenses, if any, subject to the Cap (defined below); provided that Partner notifies
Affymetrix in writing within thirty (30) calendar days of any claim or suit being made or brought and 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 9 

 
notified to Partner, and Partner gives Affymetrix authority to defend or, upon consultation with Partner, settle any such suit or proceeding, and all reasonably requested information, and
assistance necessary to settle or defend such suit or proceeding. 
 Affymetrix shall not be bound in any manner by any
settlement made without its prior express written consent. In the event that an Affymetrix Product is held to infringe as set forth above, and its use is enjoined, Partner may (a) terminate this Agreement without any further payment or
obligation to Affymetrix or (b) request that Affymetrix either obtain for Partner the right to continue using such affected Affymetrix Product, modify it to become non-infringing, or grant Partner a
credit and accept return of such unused Affymetrix Product. Notwithstanding the foregoing, Affymetrix will have no liability hereunder to the extent that the alleged or actual infringement arises: (1) from use of the Affymetrix Product in a
manner not authorized by Affymetrix in Section 2.01; (2) from combination of the Affymetrix Product with any product not supplied by Affymetrix under this Agreement; or (3) from any addition to or modification of the Affymetrix Product not
specified by Affymetrix. Further, Affymetrix will have no liability to the extent the allegedly infringing activity: (4) results from the particular Probe sequences represented on an Array; (5) results from a Diagnostic Product or a
Diagnostic Service (and would not have resulted from the Affymetrix Product alone or the procedures for use of such Affymetrix Product as specified by Affymetrix); or (6) occurs after Affymetrix has provided Partner with a design or work around
that is satisfactory to Partner or a license at Affymetrix’s cost. 
 In no event shall Affymetrix’s aggregate,
cumulative liability arising out of or relating to this Agreement (including Affymetrix’s indemnity obligations described in this section), exceed the amount of all payments made by Partner under this Agreement for the purchase of Affymetrix
Products and Commissions during the Term (the “Cap”); provided, however, that the Cap shall not apply with respect to any liability arising out of Affymetrix’s gross negligence or willful misconduct. The Cap is cumulative but
shall not include expenses incurred by Affymetrix in connection with its own legal fees. The existence of one or more claims or suits will not enlarge the Cap. Partner shall indemnify and hold harmless Affymetrix and its Affiliates and its and their
officers, directors, employees, agents and representatives for third party claims arising from Partner’s commercialization of Diagnostic Products or Diagnostic Services and any damages (including reasonable costs of investigation or settlement
and legal fees and accounting expenses) resulting therefrom subject to the Cap, except to the extent such claims or damages result from Affymetrix’ s negligence, willful misconduct, or breach of this Agreement. 

THE FOREGOING PROVISIONS OF THIS SECTION STATES THE ENTIRE LIABILITY AND OBLIGATION OF THE PARTIES, AND THE EXCLUSIVE REMEDY
OF PARTNER AND ITS AFFILIATES, WITH RESPECT TO ANY ALLEGED OR ACTUAL INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, AND ARE IN LIEU OF ALL WARRANTIES OF NON-INFRINGEMENT, EXPRESS OR IMPLIED. 

Section 5.05 Liability Limitation. 

EXCEPT TO THE EXTENT CAUSED BY A PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, EACH PARTY AND ITS REPRESENTATIVES SHALL
HAVE NO LIABILITY FOR ANY LOSS OF USE OR PROFITS, PROCUREMENT OF SUBSTITUTE GOODS OR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES OF ANY KIND, HOWEVER CAUSED AND REGARDLESS OF FORM OF ACTION WHETHER IN CONTRACT,
TORT (INCLUDING NEGLIGENCE), STRICT PRODUCT LIABILITY OR OTHERWISE, EVEN IF A PARTY OR ITS REPRESENTATIVE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. AS TO ANY AFFYMETRIX 

  
 10 

 
LIABILITY NOT LEGALLY SUBJECT TO THE FOREGOING, AFFYMETRIX LIABILITY SHALL NOT EXCEED THE CAP EXCEPT TO THE EXTENT CAUSED BY AFFYMETRIX’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. PARTNER
UNDERSTANDS AND HEREBY AGREES THAT THE RISKS OF LOSS HEREUNDER ARE REFLECTED IN THE PRICE OF THE FINANCIAL TERMS OF THIS AGREEMENT AND THAT THESE TERMS WOULD HAVE BEEN DIFFERENT IF THERE HAD BEEN A DIFFERENT ALLOCATION OF RISK. 

Section 5.06 Insurance. 

Partner agrees to procure and maintain in full force and effect throughout the Term, valid and collectible insurance policies
in connection with its activities as contemplated hereby which policies shall provide for the following types of and amounts of coverage as set forth on Schedule D attached hereto. Partner shall give Affymetrix at least thirty
(30) calendar days’ prior written notice of any policy cancellation. Upon ten (10) days written request from Affymetrix, Partner shall provide to Affymetrix a certificate of coverage or other written evidence reasonably satisfactory
to Affymetrix of such insurance coverage. Each of Partner’s liability policies required under this Section 5.06 shall name Affymetrix, and such other entities or persons as Affymetrix may designate, as an additional insured. Such policies
shall be primary insurance to any other insurance that may be available to Affymetrix. Any other insurance available to Affymetrix shall be non-contributing with and in excess to such insurance. 

Section 5.07 Assignment. 

Neither this Agreement nor any rights under this Agreement may be assigned or otherwise transferred by either Party, in whole
or in part, including by way of sale of assets, merger or consolidation without the prior written consent of the other Party other than: (i) to an Affiliate of such Party that assumes all rights and duties thereunder and is at least as
creditworthy as the assigning Party; or (ii) in connection with a Change of Control of a Party (to include the disposition of all or substantially all of such Party’s diagnostic business). 

Section 5.08 Governing Law. 

This Agreement, including all matters of construction, validity and performance shall be governed by and construed and enforced
in accordance with the laws of the State of California without regard to its conflict of laws rules and notwithstanding the actual residence of the Parties. 

Section 5.09 Arbitration. 

All disputes, differences of opinion, or controversies which may arise between the Parties out of or in relation to or in
connection with this Agreement or the breach thereof, shall be finally settled by binding arbitration in San Diego, California under the rules of American Arbitration Association in force at the time. The arbitration shall be conducted by three
(3) arbitrators selected in accordance with the rules of the AAA and the Parties shall use commercially reasonable efforts to complete the arbitration proceedings within three (3) months. Notwithstanding the foregoing, all disputes with
respect to: (a) the validity or infringement of patent rights of either Party, and (b) satisfaction of payment obligations, shall be subject to applicable federal court jurisdiction and not be subject to the arbitration proceedings set
forth in this Section 5.09. 

  
 11 

 Section 5.10 Schedules. 

Schedules A-F are hereby incorporated by reference. In the event of a conflict
between the terms set forth in the main body of this Agreement and the terms set forth in a Schedule, the terms of the main body of the Agreement will prevail. 

Section 5.11 Termination of 2014 Agreement. 

The Parties agree that, concurrent with the commencement of this Agreement on the Effective Date, the 2014 Agreement shall
terminate by mutual consent. Such termination shall be automatic without the need to be further evidenced in writing. The Parties agree to cooperate in good faith in managing and resolving any operational issues related to the transition from the
2014 Agreement to this Agreement. Affymetrix hereby releases Partner from its obligation under the last sentence of Section 5.03 of the 2014 Agreement (Obligations Upon Termination) to purchase all inventory on-hand (built per a PO from
Partner and no greater than the amount in such PO) associated with the supply of Affymetrix Products pursuant to the 2014 Agreement. 

Survival of Payment Obligations under 2014 Agreement. Notwithstanding the termination of the 2014 Agreement,
Partner’s outstanding payment obligations under the 2014 Agreement survive and are not extinguished, released or otherwise impaired by the termination of the 2014 Agreement. Such outstanding payment obligations, and the schedule for paying
them, are set forth in the Payment Plan, which is attached to this Agreement as Schedule F, and is hereby incorporated by reference (“Payment Plan”). Partner hereby affirms the amounts due as set forth in the Payment Plan,
and agrees to pay them in accordance with the schedule set forth in Schedule F. Partner acknowledges and agrees that any outstanding payment obligations under the 2014 Agreement that are not satisfied by Partner’s adherence to the
Payment Plan (or by other means mutually agreed to by the Parties in writing) are and shall remain fully enforceable by Affymetrix in accordance with the terms of this Agreement. 

[Signatures follow] 

  
 12 

 IN WITNESS WHEREOF, the Parties hereto intending legally to be bound hereby,
have each caused this Agreement to be duly executed as of the Effective Date. 
  

									
	AFFYMETRIX, INC., part of Thermo Fisher Scientific Inc.	 		 	 DECIPHER BIOSCIENCES, INC.

					
	 By:
	 	 /s/ Will Kruka
	 		 	 By:
	 	 /s/ Brent Vetter

	 Name:
	 	 Will Kruka
	 		 	 Name:
	 	 Brent Vetter

	 Title:
	 	 VP/GM
	 		 	 Title:
	 	 CFO

	 Date:
	 	 6/10/2019
	 		 	 Date:
	 	 6/7/2019

  
 13 

 SCHEDULE A 

PRODUCT PRICES 
  

			
	Pricing for Arrays	  	[***]
		
	 Reagents
	  	[***]

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 14 

 SCHEDULE B 

Affymetrix 
 Terms and Conditions
of Sale 
 1. General. These Terms and Conditions of Sale (“Terms and Conditions”) shall govern the sale and license to the
original purchaser (“Buyer”) of probe arrays, assays, reagents, instruments, software, and other products and related services (“Products”) from Affymetrix, one of its subsidiaries or authorized sellers named on the invoice or
acknowledgement (Affymetrix, Inc. or any of its subsidiaries named on the invoice is referred to here as “Affymetrix”). These Terms and Conditions shall replace and supersede any current or future purchase orders or similar forms that are
not mutually signed by Affymetrix and Buyer. Purchase orders, once accepted by Affymetrix, are not subject to cancellation or modification by Buyer without Affymetrix’ written consent. 

2. Price. 
 (a) For Deliveries
Outside Europe: Prices exclude all insurance, freight, taxes, fees, duties and levies, which shall be payable by Buyer. 
 (b) For
Deliveries Within Europe: Prices include all insurance, duties and levies, unless stated otherwise on the quotation or invoice. Freight and handling fees will be prepaid by Affymetrix and added to the invoice for reimbursement by Buyer. 

3. Delivery. Products will be packed in Affymetrix’ standard shipping packages. Affymetrix may make partial deliveries. Affymetrix will
ship via carrier selected by Affymetrix. Delivery dates set forth on a purchase order accepted by Affymetrix are subject to change and are predicated on conditions existing at that time. Affymetrix does not guarantee any delivery dates and shall not
be responsible for any loss or damage of any kind or nature whatsoever caused by any delay in delivery irrespective of the cause of such delay. 

(a) For Deliveries Outside Europe: Tender will be FCA shipping point. Title (except for software, in which case Affymetrix shall retain title)
and risk of loss or damage will pass to Buyer upon delivery of the Products to the carrier. 
 (b) For Deliveries Within Europe: Products
shall be Delivered Duty Paid Excluding VAT (DDP Ex VAT) to the Buyer’s site and the Buyer will be the importer for the Products and be responsible for paying VAT or similar taxes within the Buyer’s country. Title (except for software, in
which case Affymetrix shall retain title) and risk of loss or damage will pass to Buyer upon delivery of the Products to the carrier. 
 4.
Rejection. Any claims for damaged, missing or defective Product must be reported in writing to Affymetrix by Buyer within five (5) days from the date of receipt of Product. For any valid claim made, Affymetrix shall repair or replace the
Product. The foregoing shall be Buyer’s sole and exclusive remedy for damaged or missing Products, and, except for express warranty rights, for defective Products. 

5. Payment. Buyer will be invoiced at the time of shipment of each Product. Buyer shall make payment in full within thirty (30) days of
the date of the invoice. Late payments may incur a charge at the rate of one and one-half percent (1.5%) percent per month, or the maximum allowed by law, whichever is less. Further shipment of Products may be
declined without advance notice if Buyer fails to make any payment when due, or if the financial condition of Buyer becomes unsatisfactory to Affymetrix. Affymetrix may elect to retain a security interest in all Products sold to Buyer to secure all
of Buyer’s obligations to Affymetrix under these Terms and Conditions, and Buyer will execute any documents necessary to create and perfect this interest. Sales by Affymetrix shipped outside the U.S. may require payment on an irrevocable letter
of credit reasonably acceptable to Affymetrix. 
 6. Limited Warranty. 

 

	 	•	 	 For new instruments, Affymetrix warrants only to Buyer for the period that is the shortest of
(i) thirteen (13) months from the date of shipping; (ii) one (1) year from the date of installation; or (iii) the shortest period specified in the Affymetrix sales quote for limited-life parts, that the operating software and
instruments are free from defects in material and workmanship and conform to Affymetrix’ published specifications in all material respects. 

  

	 	•	 	 For refurbished instruments, Affymetrix warrants only to Buyer for a period that is the shortest of (i) one-hundred twenty (120) days from shipment; (ii) ninety (90) days from the date of installation; or (iii) the shortest period specified in the Affymetrix sales quote for limited-life parts,
that the operating software and instruments are free from defects in material and workmanship and conform to Affymetrix’ published specifications in all material respects. 

 

	 	•	 	 For used instruments, Affymetrix warrants only to Buyer for the period that is the shortest of (i) thirty
(30) days from date of shipment: (ii) twenty (20) days from the date of installation or (ii) the shortest period specified in the Affymetrix sales quote for limited-life parts, that the instruments and operating software are free from
defects in material and workmanship and conform to Affymetrix’ published specifications in all material respects. 

  

	 	•	 	 For all instruments, warranty service will be provided pursuant to Affymetrix’ standard service terms and
conditions enumerated therein. Affymetrix’ sole and exclusive liability (and Buyer’s sole and exclusive remedy) under the foregoing warranty shall be the repair or replacement of instruments, as solely determined by Affymetrix.
Nonconforming instruments will be serviced at Buyer’s facility or, at Affymetrix’ option, Affymetrix’ facility. 

  
 15 

	 	•	 	 For probe arrays or reagents reasonably determined by Affymetrix to be defective, independent of user error,
shall be replaced by Affymetrix on a 1:1, like-kind basis at no cost to Buyer or at Affymetrix’ discretion, as a credit for future purchases, provided that such defective probe arrays or reagents were used by Buyer prior to their expiration
date, or if there is no expiration date, the Products were used within six (6) months of receipt. The defect must be reported within thirty (30) days of discovery with appropriate detail to Affymetrix’ Technical Support team. If the
cause of the failure was due to an Affymetrix instrument malfunction, a replacement will be granted only during the instrument warranty period or if the instrument is under an instrument service contract, pursuant to the terms and conditions then in
effect. Third party reagents or consumables not purchased from or provided by Affymetrix are not covered under Affymetrix warranty. 

  

	 	•	 	 For Affymetrix Methods for Automated Target Preparation for GeneTitan®, subject to the conditions and limitations of liability stated herein, Affymetrix warrants, for one (1) year from the date of installation (“Warranty Period”) of the GeneTitan®, for the Buyer’s benefit that the Affymetrix methods for automated target preparation for the GeneTitan® family of instruments (the
“Method”) shall operate substantially in accordance with the accompanying documentation provided that; 

(i) the Method is installed by a qualified Affymetrix representative, (ii) the automated target preparation instrument is
installed by a qualified engineer and maintained under a valid service contract or warranty with the third party vendor, (iii) the Method is operated in accordance with the supplied technical instruction from Affymetrix, (iv) that the
associated storage media on which the Method resides is free from defects in material and workmanship. The foregoing warranty shall not apply to (i) Methods that are modified; (ii) Methods that are not the then-current version;
(iii) problems caused by Buyer’s negligence or error, a hardware malfunction or other causes beyond the control of Affymetrix; or (iv) Methods installed in an operating environment or in a hardware environment not strictly complying
with the Affymetrix specifications required for the Method set forth in the documentation. The warranty stated herein for the Methods do not cover damage to the automated target preparation instrument nor associated consumables and reagents not
supplied by Affymetrix. 
  

	 	•	 	 Technical Assistance: Affymetrix, may, but is not obligated to, furnish technical assistance and information
with respect to the Products. Any suggestions by Affymetrix regarding use, selection, application or suitability of the Products shall not be construed as a warranty. 

Except as provided above, any warranty provided herein does not apply to any consumables, including third party reagents, or to any defect
caused by Buyer’s failure to provide a suitable storage, use, or operating environment, use of non-recommended reagents, spills, or the use of the Products for a purpose or in a manner other than that for
which they were designed, modifications or repairs done by Buyer, or any other abuse, misuse, or neglect of the Products. Affymetrix is not responsible for any costs or expenses incurred by the Buyer due to downtime. Affymetrix may at any time stop
providing and supporting the Products (“End of Life”) and will use commercially reasonable efforts to communicate such End of Life events in advance. This warranty applies only to Buyer, and not third parties. Furthermore, this Warranty
stated herein shall not apply to product performance failures that are caused by users of the Affymetrix Products who were not trained on and qualified to use the Affymetrix Products and assays by an Affymetrix field service engineer, Affymetrix
application specialist, or an authorized Affymetrix seller. The foregoing is not intended to limit any warranty extended to Buyer by a third party original equipment manufacturer of a Product or component thereof, provided that any remedy received
by Buyer under any such warranty shall relieve Affymetrix of its obligations with respect to the subject of such remedy. TO THE EXTENT PERMITTED BY APPLICABLE LAW, AFFYMETRIX AND ITS SUPPLIERS DISCLAIM ALL OTHER REPRESENTATIONS AND WARRANTIES,
EXPRESS OR IMPLIED, WITH RESPECT TO PRODUCTS AND SERVICES, INCLUDING BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, SATISFACTORY QUALITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.

 7. Pre-release Products (Not Applicable to Products Marketed for IVD Use). If any Product is a
beta, technology access, early access, or other pre-commercial release version (“Pre-release Product”), then this Section applies. To the extent that any
provision in this Section is in conflict with any other term or condition in these Terms and Conditions, this Section shall supersede such other term(s) and condition(s) with respect to the Pre-release
Product, but only to the extent necessary to resolve the conflict. Buyer acknowledges that the Pre-release Product is a pre-release version, does not represent final
product from Affymetrix, and may contain defects, bugs, errors and other problems that could cause system or other failures, sample loss and data loss. CONSEQUENTLY, THE PRE-RELEASE PRODUCT IS PROVIDED TO YOU
“AS IS” AND AFFYMETRIX DISCLAIMS ALL WARRANTIES (INCLUDING THE LIMITED WARRANTY SET FORTH ABOVE) AND ALL LIABILITY OBLIGATIONS TO BUYER OF ANY KIND. Buyer acknowledges that Affymetrix has not promised or guaranteed to Buyer that Pre-release Product will be announced or made available to anyone in the future, that Affymetrix has no express or implied obligation to Buyer to announce or introduce the
Pre-release Product and that Affymetrix may elect not to introduce a product similar to or compatible with the Pre-release Product. Accordingly, Buyer acknowledges that
any research or development that Buyer performs using the Pre-release Product or any product associated with the Pre-release Product is done entirely at Buyer’s own
risk. 
 8. Limited License. Subject to these Terms and Conditions, and to the terms and conditions of any license provided by Affymetrix
that is specific to a particular Product (which shall govern with respect to such Product in the event of conflict with these Terms and Conditions), Affymetrix hereby grants to Buyer a non-exclusive, non-transferable, non-sublicensable license to use the Product(s) provided to Buyer by Affymetrix only in accordance with the manuals and written instructions provided by
Affymetrix. Buyer understands and agrees that except as expressly set forth in these Terms and Conditions (or in the Affymetrix-provided license specific to a particular Product), no right or license to any patent or other intellectual property
owned or licensable by 

  
 16 

 
Affymetrix is conveyed or implied by these Terms and Conditions or any Product. In particular, no right or license is conveyed or implied to use any Product provided hereunder in combination with
a product not provided, licensed or specifically recommended by Affymetrix for such use. 
 9. Product Uses. Products of Affymetrix which
are or may be drugs, food additives or diagnostic reagents, as described in the federal food, drug and cosmetic act, are for investigational use only in laboratory research animals or testing in vitro, and are not for drug, new drug, veterinary
drug, food, food additive or human use. Unless otherwise indicated, all products are distributed and sold for chemical purposes only, not for drug use or for application to or ingestion by humans or for commercial horticulture use, for pesticide
use, for application to or ingestion by animals or for veterinary drug use. All products sold by Affymetrix to Buyer shall be used by qualified professionals only. The burden for safe use and handling of all products sold by Affymetrix to Buyer is
entirely the responsibility of Buyer and anyone who purchases the goods from Buyer and uses them. Absence of hazardous warnings does not imply non-toxicity. 

10. Products Marketed for Research Use Only. 
  

	 	(a)	 Products marketed by Affymetrix for research use only do not have the approval or clearance of the U.S. Food
and Drug Administration (“FDA”) or other regulatory approval, clearance or registration for in vitro diagnostic (“IVD”) use. No license is conveyed or implied for Buyer to use, and Buyer agrees not to use, such Products in any
manner requiring FDA or other regulatory approval, clearance or registration relating to IVD use. 

  

	 	(b)	 Affymetrix’ goods that are intended for research purposes may not be on the Toxic Substances Control
Act (“TSCA”) inventory. Buyer assumes responsibility to ensure that the goods purchased from Affymetrix are approved under TSCA, if applicable. Consistent with Buyer’s agreement to comply with all TSCA and Research and Development
substance exemption (the “R&D exemption”) requirements applicable to the purchase, Buyer agrees and warrants that Buyer will comply with all the requirements necessary to maintain the R&D exemption, including using the R&D
substance under the supervision of a technically qualified individual, maintaining all necessary labeling, and providing all necessary notifications. Buyer also agrees and warrants that Buyer will use or sell (if so authorized) the R&D substance
exclusively for R&D purposes or specified exempt commercial purposes. Buyer specifically agrees and warrants that Buyer will not sell or distribute the R&D substance to consumers. 

11. Products Marketed for In Vitro Diagnostic Use. Products marketed by Affymetrix for IVD use have been cleared by the FDA, and CE marked in
the European Union, for IVD use. No license is conveyed or implied for Buyer to use, and Buyer agrees not to use, such Products in any manner requiring other regulatory approval, clearance or registration relating to IVD use. The Affymetrix GeneChip® Array Instrumentation System for IVD use requires calibration and maintenance twice a year by authorized Affymetrix personnel to ensure system performance. Failure to maintain the system as
recommended may result in the failure of the system to perform in accordance with specifications published by Affymetrix. 
 12. Use
Restrictions. Buyer is not licensed to, and agrees not to: (a) resell any Affymetrix-supplied probe array or reagent, unless otherwise authorized by Affymetrix in writing (b) transfer, or distribute any Affymetrix-supplied probe array or
reagent, directly or indirectly, to any third party for any purpose or use, except as otherwise approved by Affymetrix in writing; (c) use or allow anyone to use any Affymetrix-supplied probe array or reagent more than once, or dilute any
Affymetrix-supplied reagent; or (d) provide a fee-for-service or other non-collaborative sample processing service to third
parties using an Affymetrix-supplied probe array or reagent (e.g., wherein the service provider offers standardized services for standardized fees to multiple third parties, the customer does not contribute scientifically to the services performed,
and all rights to the results and discoveries derived therefrom are transferred to the customer). 
 13. Product Improvements. Except to the
extent prohibited by applicable law, Buyer hereby grants to Affymetrix a non-exclusive, worldwide, fully paid-up, royalty-free license to all Product Improvements
provided that if the Product Improvements are incorporating Buyer’s proprietary technology or intellectual property, Buyer shall not be required to grant Affymetrix a license to such proprietary technology or intellectual property. Buyer need
not disclose any Product Improvements to Affymetrix except as may be reasonably required to comply with the foregoing license. For purposes of this Section, a “Product Improvement” shall mean any invention conceived or reduced to practice
using a Product that relates to(a) design, manufacturing, layout or packaging of nucleic acid probes or probe arrays; (b) manual or automated assay techniques that may be used in connection with probe arrays or similar products (including
techniques related to nucleic acid extraction, amplification, labeling, dilution and other processes); or (c) software analysis techniques relating to the extraction or storage of data generated using probe arrays. “Product
Improvements” shall not include data generated using Products or discoveries derived therefrom (except as expressly set forth in (a) - (c) above). 

14. Target Sequence Confidentiality for Custom Products. If Buyer discloses to Affymetrix a confidential set of nucleic acid or peptide target
sequences (“Target Sequences”) for which Buyer desires Affymetrix to design and manufacture custom probe arrays or custom protein assay or custom nucleic acid assay pursuant to these Terms and Conditions, upon Buyer’s written request,
Affymetrix agrees to not disclose or use such confidential information disclosed to it by Buyer for any purpose other than designing and manufacturing such Products, supplying them to Buyer and/or other parties designated by Buyer, otherwise
performing its obligations to Buyer (and any obligations Affymetrix may have to such other parties), and for other purposes authorized by Buyer. The provisions of this Section shall not apply to any information which (a) is known or used by
Affymetrix prior to Buyer’s disclosure to Affymetrix; (b) is disclosed to Affymetrix by a third party under no obligation of confidentiality to Buyer; (c) is or becomes published or generally known to the public through no fault of
Affymetrix; or (d) is independently developed without reference to such confidential information disclosed to Affymetrix by Buyer. Notwithstanding the foregoing, Affymetrix shall be permitted to disclose such information in order

  
 17 

 
to comply with applicable laws, a court order, or governmental regulations, provided that Affymetrix has provided Buyer with prior notice of such disclosure, to the extent reasonably practicable.
Affymetrix’s obligations under this Section shall terminate three (3) years following the date of disclosure. 
 15. Target
Sequence Responsibility. Buyer shall be fully responsible for the Target Sequences, including the obtaining of all required consents, and Buyer agrees to indemnify Affymetrix and its employees, officers, directors, representatives, contractors,
suppliers and any affiliate of the foregoing (the “Affymetrix Group”) and hold each of them harmless from and against any losses, liabilities, demands, damages, costs and expenses, including without limitation reasonable legal fees and
expenses, arising from or relating to the Target Sequences or their use. Buyer agrees to fully cooperate with the Affymetrix Group and its counsel in its defense and preparation for any such action or proceeding. 

16. Liability Limitation. EXCEPT TO THE EXTENT CAUSED BY AFFYMETRIX’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, OR REQUIRED BY APPLICABLE
LAW, AFFYMETRIX SHALL HAVE NO LIABILITY FOR ANY LOSS OF USE OR PROFITS, PROCUREMENT OF SUBSTITUTE GOODS OR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, OR SPECIAL DAMAGES OF ANY KIND, HOWEVER CAUSED AND REGARDLESS OF FORM OF ACTION WHETHER IN CONTRACT,
TORT (INCLUDING NEGLIGENCE), STRICT PRODUCT LIABILITY OR OTHERWISE, EVEN IF AFFYMETRIX HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; AS TO ANY AFFYMETRIX LIABILITY NOT LEGALLY SUBJECT TO THE FOREGOING, AFFYMETRIX’S LIABILITY SHALL NOT
EXCEED THE AMOUNT PAID BY BUYER TO AFFYMETRIX DURING THE TERM OF THE AGREEMENT. BUYER UNDERSTANDS THAT THE RISKS OF LOSS HEREUNDER ARE REFLECTED IN THE PRICE OF THE PRODUCTS AND THAT THESE TERMS WOULD HAVE BEEN DIFFERENT IF THERE HAD BEEN A
DIFFERENT ALLOCATION OF RISK. 
 17. Export Controls. Buyer acknowledges that the Products and related materials may be subject to export
controls under the U.S. Export Administration Regulations and related U.S. laws. Buyer will (a) comply strictly with all legal requirements established under these controls, (b) cooperate fully with Affymetrix in any official or unofficial
audit or inspection that relates to these controls and (c) not export, re-export, divert, transfer or disclose, directly or indirectly, any Product or related technical documents or materials or any
direct product thereof to any country (or to any national or resident thereof which the U.S. Government determines from time to time is a country (or end-user) to which such export, re-export, diversion. transfer or disclosure is restricted, without obtaining the prior written authorization of Affymetrix and the applicable U.S. Government agency. 

18. Unforeseen Events. Affymetrix shall not be liable for delay or failure in performance of any obligations hereunder if performance is
rendered impracticable by the occurrence of any condition beyond the reasonable control of Affymetrix. In the event of any such delay or failure in performance, Affymetrix shall have such additional time within which to perform its obligations
hereunder as may reasonably be necessary under the circumstances. 
 19. Miscellaneous. These Terms and Conditions constitute the entire
agreement between Buyer and Affymetrix with respect to the subject matter hereof and is the final, complete, and exclusive statement of the terms of the agreement, superseding all prior written and oral agreements, understandings and undertakings
with respect to the subject matter hereof. The waiver of any provision or any breach thereof shall not affect any other provision of these Terms and Conditions. The U.N. Convention on Contracts for the International Sale of Goods shall not apply to
these Terms and Conditions. In the event that any provision of this Agreement or portion thereof is found to be illegal or unenforceable, the Agreement shall be construed without the unenforceable provision or portion thereof. 

20. Governing Law. 
 (a) For
Deliveries Outside Europe: To the extent permitted by applicable law, these Terms and Conditions shall be governed by and construed according to the laws of California, without regard to conflict of law provisions. 

(a) For Deliveries Within Europe: To the extent permitted by applicable law, these Terms and Conditions shall be governed by and construed
according to the laws of England, without regard to conflict of law provisions. 

  
 18 

 SCHEDULE C 

REGULATORY TERMS AND CONDITIONS 

“Regulatory Approval” means all approvals, registrations, certifications or market clearances required by
Regulatory Authorities. 
 “Regulatory    Authorities” means all governmental
agencies regulating the development, manufacture or use of Diagnostic Products or Diagnostic Services in any country or groups of countries. 

1. Regulatory Approvals. 

Partner shall, before its marketing, selling or distributing Diagnostic Products or Diagnostic Services for diagnostic
purposes, obtain Regulatory Approval for Partner’s Diagnostic Products. Affymetrix shall assist Partner in obtaining such Regulatory Approval, including without limitation, supply Partner with existing information regarding the Arrays or their
manufacture or use, that is necessary or useful for Partner’s regulatory filings on reasonable terms and conditions. Partner shall have the right to use and distribute Arrays for the purpose of investigational studies to determine the
performance characteristics of the Array prior to and, if necessary, after the Regulatory Approval of the Diagnostic Product incorporating such Arrays. Partner shall comply with regulatory requirements for investigational use in any territory in
which such Arrays are used. Partner is responsible for all design control activities relating to Partner’s use of the Arrays. 

Affymetrix will promptly provide existing applicable information to fulfill a Regulatory Authority’s inquiries and/or
requirements relating to a change in Affymetrix products or labeling. 
 Affymetrix will promptly notify Partner if it has
received written communication from any Regulatory Authority stipulating or threatening the stipulation of the cessation of the production or sale of the Arrays. 

Affymetrix will provide reasonable regulatory support to Partner in connection with or in support of US Class I or
Class II or CE Mark assay submission to a Regulatory Authority for Regulatory Clearance or Approval. Affymetrix will supply a right of reference letter for Partner to include in its assay submission so that FDA may access information within the
510(k) file for the [***]. As the [***] is currently self-certified under the IVDD directive, no cross reference to a Regulatory Authority is required for CE marking of Partner’s assay. Partner represents and warrants that the information
supplied by Partner to Affymetrix in connection with or in support of any submission to a Regulatory Authority for Regulatory Approval shall be accurate and complete and shall have been obtained in compliance with all applicable laws and
regulations, and Partner hereby gives Affymetrix permission to use and cross-reference such information as is required in connection with any regulatory filing relating to products for use with Diagnostic Products or Diagnostic Services. 

Partner covenants that all Diagnostic Products and Diagnostic Services provided by Partner in connection with this Agreement
(i) shall be designed, offered for sale or distribution and provided in a good and workmanlike manner, (ii) shall be designed, offered for sale or distribution and provided in compliance with this Agreement, and (iii) shall comply
with all applicable statutes, laws, ordinances and regulations then applicable to the design, performance and supply of such Diagnostic Products or Diagnostic Services (as the case may be), including, without limitation, those enforced or prescribed
(A) 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
by the United States Food and Drug Administration (including compliance with good manufacturing practices) if sold with the U.S., (B) by the International Standards Organization (ISO) (if Partner
claims or otherwise represents compliance with any ISO standard(s)) when applicable, and (C) by any other relevant local authorities. 

Partner shall indemnify and hold harmless Affymetrix and its Affiliates and their officers, directors, employees, agents and representatives
for any breach of the foregoing covenant. 
 2. Notice of Defects and Deviations. 

Each Party shall immediately notify the other in writing, in no event more than three (3) days from date of discovery,
should it become aware, through Partner complaint or otherwise, of any defect or condition which may render any Instrument, Array or related reagent sold to a diagnostic end user in violation of FDA and/or any other applicable laws, rules or
regulations, or which may in any way deviate from the quality, specifications or warranties for any Instrument, Array or related reagent. 

3. Recalls. 

The Parties agree to cooperate with each other to enable them to satisfy their obligations as licensed
manufacturers/distributors of Instruments, Arrays or related reagents sold to diagnostic end users with respect to recalls, advisory notices, or field corrective actions relating to such Instruments, Arrays or reagents. 

4. Medical Device Reporting (MDR)/Reportable Incident. 

In the event that a Party becomes aware of information, from any source, that reasonably suggests that an Instrument, Array or
reagent manufactured by Affymetrix sold to a diagnostic end user may have caused or contributed to a death or serious injury or has malfunctioned and if the malfunction were to recur, it would likely cause or contribute to a death or serious injury,
then such Party shall (i) notify the other via phone call to such Party’s authorized representative for regulatory affairs as soon as possible, and in any case within 72 hours for serious injury or death, and (ii) immediately notify
the other in writing of the facts surrounding such situation to the best knowledge of the Party providing the notice. The Parties shall cooperate and work together to obtain details to make the MDR decision to meet reporting requirements by any
applicable governmental regulation, law, or other requirement. Both Parties shall use commercially reasonable efforts to investigate fully the root cause of any such incident or malfunction. 

5. Failure to Comply with Legal or Regulatory Regime. 

In the event that a Party to this Agreement is advised in writing by the USFDA, ISO registrar or notified body, or by an
analogous national governmental regulatory authority of the United States, the European Union or a European country or any other country in the Territory, that such Party’s activities in connection with Instruments, Arrays, or related reagents
(or products that incorporate any of the foregoing) do not comply with applicable laws and/or other regulatory requirement (excluding laws and regulations relating solely to the protection of intellectual property), the other Party will be promptly
notified in writing. The Parties agree to cooperate in good faith to resolve the regulatory authority’s concerns. Neither Party shall be required to continue activities that it has reasonable cause to believe may place it in violation of one or
more regulatory requirements. In such case, the affected Party may provide written notice to the other Party detailing the affected Party’s concerns. Unless a Party submits an acceptable written plan within thirty days of such noncompliance
notice by the Regulatory Authority that will allow such Party to achieve compliance within the following 90 days, the other Party shall no longer be required to perform under this Agreement. Upon eventual compliance by the Party with the Regulatory
Authority, the other Party shall recommence performance under this Agreement. 

 6. Review of Partner’s Use of Products. 

Affymetrix shall have a limited right to review Partner’s use of the Affymetrix Products supplied under this Agreement to
determine whether the use of such products in Partner’s Diagnostic Products and Diagnostic Services is consistent with the terms of this Agreement. Such review, if conducted, may include a review of Partner’s past ordering patterns and a
review of Partner’s Diagnostic Products and Diagnostic Services development plans and marketing information for the following two quarters. The review of Partner’s use of products and services shall be allowed [***] per year at a mutually
convenient date on the premises and during the regular business hours of Partner at the written request of Affymetrix [***] prior to the proposed review date and at the expense of Affymetrix. All information gathered by Affymetrix shall be
considered Confidential Information of Partner and shall not be removed from Partner’s premises except with the written permission of Partner and after having been stamped as Confidential Information and dated. Such review shall be allowed for
compliance verification purposes only. 
 A reciprocal right is granted to Partner to review not more than [***] a year,
with [***] prior written notice, product design and manufacturing by Affymetrix of Affymetrix Products that are supplied to Partner under this Agreement and in conformity with applicable quality control standards, under the same conditions as
provided above. 
 7. Compliance with Law. 

Affymetrix shall comply with all laws, regulations and requirements applicable to Affymetrix as a supplier of the Affymetrix
Products, including QA Standards and any other regulations promulgated from time to time by the FDA and any other governmental authority that has jurisdiction over Affymetrix’s manufacture, supply, testing, packaging, processing, storage, or
distribution of the Affymetrix Products or over any Affymetrix facility. Affymetrix represents, warrants and covenants that it has, and will continue to have and maintain throughout the term of the Agreement at Affymetrix’s expense all permits,
approvals and authorizations, including, without limitation, such approvals as may be required under applicable law, to manufacture and sell Affymetrix Products in the Territory. 

8. Records: Samples. 

Affymetrix shall keep, or cause to be kept, complete, accurate and authentic accounts, notes, data and records pertaining to
the manufacture, processing, testing, labeling, storage, and distribution of Affymetrix Products sold to Partner, including without limitation master production and control records, and shall retain, or cause to be retained, samples of such
Affymetrix Products, in each case accordance with applicable laws and regulations. Affymetrix shall retain, or cause to be retained, such records for a period of [***] years following the date of manufacture, and such retained samples for a period
of [***] after the product expiration date. Upon request, Affymetrix shall make available for Partner’s review such records and retained samples. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE D 

INSURANCE REQUIREMENTS 
  

	1.	 Commercial General Liability Insurance in an amount not less than [***] per occurrence and not less than
[***] annual aggregate, bodily injury/property damage combined. 

  

	2.	 Errors and Omissions Insurance in an amount not less than [***] per occurrence and not less than [***]
annual aggregate, bodily injury/property damage combined. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE E 

[***] 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE F 

PAYMENT PLAN 
 [***] 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]